{"title": "PDF", "author": "PDF", "url": "https://www.blacpma.usach.cl/sites/blacpma/files/006-004.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "cleaned_text": "Bolet\u00edn Latinoamericano y del Caribe de Plantas Medicinales y Arom\u00e1ticas Volumen 6, N\u00famero 4 Especial Regulaci\u00f3n de Fitomedicinas / Special Issue on Regulation of PhytomedicinesEditor/Coordinador: Jose M. Prieto A vision for medicinal plants. G.A. Cordell La regulaci\u00f3n global de los medicamentos herbarios.J.M. Prieto The Traditional Herbal Medicine Directive within the European regulatory framework for Products. The Impact of the European Traditional Use Directive on the Herbal Product Markets in the United Kingdom, Germany and Spain. W. Peschel Antecedentes y situaci\u00f3n reguladora de la medicina herbaria en Cuba. M. Gonz\u00e1lez Ram\u00edrez, D. Rem\u00edrez, O. L. Jacobo Phytomedicines in Jamaica: regulatory issues.D. Robertson An Overview on the Development in Regulation and Control of Medicinal and Aromatic Plants in the Indian System of Medicine. P.K. Mukherjee, M. Ventakesh, V. Kumar Con el auspicio Aromat. Vol. 6 (4) 2007 i Fundadores: Jos\u00e9 L. Mart\u00ednez (Chile) - Jorge Rodr\u00edguez (Cuba) Editor Jefe: Jos\u00e9 L. Mart\u00ednez (Chile) Editor Jefe Cient\u00edfico: Jos\u00e9 M. Prieto (Reino Unido) Ejecutivo: Gabino Garrido (Cuba) Asociado: Patricia Arenas (Argentina) Asociado: Carla Delporte (Chile) Co-editores Arnaldo Bandoni (Argentina) Francisco Mor\u00f3n (Cuba) Patrick Moyna (Uruguay) Damaris Silveira (Brasil) Presidente de la SLF (2005 - 2008) Horacio Heinzein (Uruguay) Consejo Editorial Christian Agyare (Ghana) Roc\u00edo Alarc\u00f3n (Reino Unido) Jorge Alonso (Argentina) Giovanni Apendino (Italia) Elizabeth Barrera (Chile) Geofrey Cordell (Estados Unidos) Marco Dehesa (Ecuador) Rene Delgado (Cuba) Eduardo Dellacasa (Uruguay) Luis Doreste (Venezuela) Mildred Garc\u00eda (Costa Rica) Martha Gattusso (Argentina) Norman Farnworth (Estados Unidos) Michael Heinrich (Reino Unido) Amelia Henriques (Brasil) Armando Herrera (M\u00e9xico) Peter Houghton (Reino Unido) Mar\u00eda In\u00e9s Isla (Argentina) Ana Ladio (Argentina) Patricia Landazuri (Colombia) Claudio Laurido (Chile) Olga Lock (Per\u00fa) Vicente Mart\u00ednez (Guatemala) Ernesto Medina (Nicaragua) Pedro Melillo de Magalhaes (Brasil) Leonora Mendoza (Chile) John A.O. Ojewole (Sudafrica) Mahendra Rai (India) Luca Rastrelli (Italia) Elsa Rengifo (Per\u00fa) Jos\u00e9 Lu\u00eds R\u00edos (Espa\u00f1a) Alicia Rodr\u00edguez (Cuba) Marcela Samarotto (Chile) Aurelio San Mart\u00edn (Chile) Guillermo Schinella (Argentina) Djaja D. Soejarto (Estados Unidos) Yen-Jen Sung (Taiw\u00e1n) Peter Taylor (Venezuela) Nilka Torres (Panam\u00e1) Ren\u00e9 Torres (Chile) Carlos Vicente (Argentina) Marcelo Wagner (Argentina) Elisabeth Williamson (Reino Unido) OBJETIVOS DEL BOLET\u00cdN Estimular a los grupos de trabajo existentes en Latinoam\u00e9rica, sean investigadores, productores, funcionarios o simplemente interesados en las plantas medicinales y arom\u00e1ticas, poniendo a su disposici\u00f3n este Bolet\u00edn para la difusi\u00f3n y la divulgaci\u00f3n de sus investigaciones y de las actividades que en general desarrollen en torno a plantas. Ser una herramienta de difusi\u00f3n para la Sociedad Latinoamericana de Fitoqu\u00edmica, principalmente, y de otras sociedades y agrupaciones que se sientan representadas por este Bolet\u00edn. Constituir un nexo entre los profesionales de habla hispana, francesa, portuguesa e inglesa de la regi\u00f3n, relacionados con el tema central del Bolet\u00edn El BOLET\u00cdN LATINOAMERICANO Y DEL CARIBE DE PLANTAS MEDICINALES Y AROM\u00c1TICAS (BLACPMA), ISSN 0717 7917, es una publicaci\u00f3n cient\u00edfica electr\u00f3nica bimensual dirigida a diversos profesionales y t\u00e9cnicos vinculados al campo de las plantas medicinales y arom\u00e1ticas. BLACPMA es una entidad sin \u00e1nimo de lucro. Aunque auspiciada por la Sociedad Fitoqu\u00edmica Latinoamericana (SLF), este bolet\u00edn no es propiedad de Club o Asociaci\u00f3n alguna. Ni BLACPMA ni la SLF son responsables en ning\u00fan momento de las opiniones vertidas en sus p\u00e1ginas, que son responsabilidad \u00fanica de sus respectivos autores. Todo el material gr\u00e1fico ha sido creado de manera genuina o bien remitido por sus autores con el permiso de \u00e9stos. Todas las marcas y logos referidos en estas p\u00e1ginas son propiedad de sus respectivos autores o empresas. En Chile, 1 de Enero de 2007. BLACPMA WEB Site: www.blacpma.cl Envio de trabajos Online a nuestra editorial (Online Submission) Blacpma_editorial@hotmail.com blacm@direct Bol. Latinoam. Caribe Plant. Med. Aromat. Vol. 6 (4) 2007 ii El BOLET\u00cdN LATINOAMERICANO Y DEL CARIBE DE PLANTAS MEDICINALES Y AROM\u00c1TICAS (BLACPMA), ISSN 0717 7917, es una publicaci\u00f3n cient\u00edfica electr\u00f3nica bimensual dirigida a diversos profesionales y t\u00e9cnicos vinculados al campo de las plantas medicinales y arom\u00e1ticas y en general dedicados a los productos naturales de inter\u00e9s medicinal o nutraceutico. Se aceptar\u00e1n trabajos relacionados con las \u00e1reas que cubre el Bolet\u00edn y que son: agronom\u00eda, antropolog\u00eda y etnobot\u00e1nica, aplicaciones industriales, bot\u00e1nica, calidad y normalizaci\u00f3n, ecolog\u00eda y biodiversidad, econom\u00eda y mercado, farm acolog\u00eda, fitoqu\u00edmica, farmacognosia, legislaci\u00f3n, informaciones y difusi\u00f3n de eventos, cursos, premios, reglamentaciones, noticias, cuestiones de mercado, ponencias, bibliograf\u00eda, o cualquier otro tipo de material que se crea importante comunicar. Se podr\u00e1n presentar trabajos de revisi\u00f3n y de investigaci\u00f3n cient\u00edfica original , comunicaciones cortas , as\u00ed como ensayos y escritos para debate escritos en idioma espa\u00f1ol, ingl\u00e9s, portugu\u00e9s o franc\u00e9s de libre extensi\u00f3n siempre que razonablemente se ajuste al objetivo del trabajo. Los anuncios, noticias y otros no deber\u00e1n exceder la cuartilla. En todos los casos est\u00e1n incluidas las tablas. Los trabajos ser\u00e1n presentados en lenguaje de Microsoft Word (versi\u00f3n 3.1 o superior, con letra Times New Roman n\u00famero 11) y enviados por correo electr\u00f3nico a la siguiente direcci\u00f3n: blacpma_editorial@hotmail.com o en su lugar por correo a\u00e9reo en disquete de 3.5 pulgadas a: Lic. Jos\u00e9 Luis Mart\u00ednez, Editor, Casilla de Correos 70036, Santiago 7, Chile. Los trabajos se acompa\u00f1ar\u00e1n de una relaci\u00f3n de los correos electr\u00f3nicos y/o direcciones postales de todos los autores. El autor principal se responsabilizar\u00e1 de la conformidad de cada uno de ellos con su publicaci\u00f3n en BLACPMA, as\u00ed como de cualquier problema surgido por la autor\u00eda y/o originalidad del trabajo. Una vez recibidos, los trabajos se enviar\u00e1n a dos evaluadores que decidir\u00e1n su aprobaci\u00f3n o rechazo. Los trabajos se dividir\u00e1n en Introducci\u00f3n, Materiales y M\u00e9todos, Resultados, Discusi\u00f3n y Conclusiones y Bibliograf\u00eda. En cualquiera de las modalidades en la cual se presenten los trabajos, en la primera p\u00e1gina deber\u00e1 aparecer: T\u00edtulo del trabajo (en espa\u00f1ol e ingl\u00e9s), autores, instituci\u00f3n a la cual pertenecen los autores, direcci\u00f3n del autor principal y correo electr\u00f3nico. Deber\u00e1 aparecer adem\u00e1s un resumen en espa\u00f1ol e ingl\u00e9s de no m\u00e1s de 100 palabras, un t\u00edtulo corto y un m\u00e1ximo de 6 palabras clave. Los n\u00fameros de las tablas y las figuras deben ser ar\u00e1bigos. Las citas en el texto deber\u00e1n incluir apellido del autor y a\u00f1o, separados por coma y colocados entre par\u00e9ntesis (ejemplo: Bruneton, 1995); si hay m\u00e1s de una trabajo del mismo autor, se separar\u00e1n por comas (ejemplo: Bruneton, 1987, 1995, 2001). Si hay dos autores se citar\u00e1n separados por \"y\" o su equivalente, respetando el idioma original de la fuente. Si hay m\u00e1s de dos autores, s\u00f3lo se citar\u00e1 el primero seguido de la expresi\u00f3n et al. destacada en it\u00e1lica (ejemplo: Dixon et al., 1999), en tanto que en la bibliograf\u00eda deber\u00e1n figurar todos los autores. Si hay varios trabajos de un mismo autor y a\u00f1o, se citar\u00e1 con una letra en secuencia adosada al a\u00f1o (ejemplo: Mayer et al. 1987a, 1987b). Si un trabajo no tiene autor, se lo citar\u00e1 como An\u00f3nimo seguido de la fecha de publicaci\u00f3n. Si hubiera m\u00e1s de una cita de este tipo en el mismo a\u00f1o, se adosar\u00e1 una letra correlativamente (An\u00f3nimo, 2002a, An\u00f3nimo, 2002b). La bibliograf\u00eda incluir\u00e1 s\u00f3lo las referencias citadas en el texto, ordenadas alfab\u00e9ticamente por el apellido del primer autor, sin n\u00famero que lo anteceda y sin sangr\u00eda. Apellido/s del autor seguido de las iniciales del nombre sin puntos ni separaci\u00f3n entre ellas. El nombre de la revista se colocar\u00e1 abreviado seg\u00fan normativa ISO y en it\u00e1lica de acuerdo con el Botanico Periodicum Huntianum, (disponible solamente en edici\u00f3n impresa) o con el mas conveniente Pubmed Journals Database (http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=Journal , ISO abbreviation), que ofrece la posibilidad de chequear online el nombre y abreviatura (en ambos sentidos) de un enorme n\u00famero de revistas. Por ultimo se citar\u00e1 el volumen de la publicaci\u00f3n, mejor si seguido del n\u00famero entre par\u00e9ntesis, dos puntos y el n\u00famero de p\u00e1gina desde x hasta y, sin espacios entre medio. Las citas de libros deben explicitar que p\u00e1ginas fueron consultadas y el a\u00f1o de edici\u00f3n (presten atenci\u00f3n a no equivocar el a\u00f1o de la prim era edici\u00f3n con el de la edici\u00f3n que est\u00e1n Uds. consultando). No se admitir\u00e1n citas inco mpletas y todo defecto ser\u00e1 motivo de retraso del art\u00edculo hasta su correcci\u00f3n acuerdo a estas normas. Instrucciones para los autores Bol. Latinoam. Caribe Plant. Med. Aromat. Vol. 6 (4) 2007 iii MODELOS Publicaciones peri\u00f3dicas Soto H, Rovirosa J, San Mart\u00edn A, Argando\u00f1a V. 1994. Metabolitos secundarios de Dictyota crenulata. Bol. Soc. Qu\u00edm. 39(3):173-178. Libros Durand E, Miranda M, Cuellar A.1986. Manual de pr\u00e1cticas de laboratorio de Farmacognosia. Ed. Pueblo y Educaci\u00f3n, La Habana, Cuba, pp. 90, 120-121. Cap\u00edtulos de libros editados Lopes de Almeida JM. 2000. Formulaci\u00f3n farmac\u00e9utica de productos f itoterap\u00e9uticos, pp. 113- 124. En Sharapin N: Fundamentos de tecnolog\u00eda de productos fitoterap\u00e9uticos. Ed. CAB y CYTED, Bogot\u00e1, Colombia. Tesis (aceptable s\u00f3lo si no hay fuente alternativa) Gonz\u00e1lez de Cid D. 2000. Estudio de cianobacterias con efectos nocivos (delet\u00e9reos y t\u00f3xicos) en ambientes acu\u00e1ticos de la provincia de San Lu\u00eds. Tesis Doctoral, Universidad Nacional de San Lu\u00eds, Argentina, pp. 234, 245-244. Comunicaciones a Congresos Si no hay libro oficial de abstracts: Novak A, Pardo de Santayana M, Prieto JM. 2006. Antioxidant activity as anti-inflammatory remedies. Comunicaci\u00f3n a la British Pharmaceutical Conference 2006 (Royal Pharmaceutical Society of Great Britain, Manchester, UK, 4-6 Septiembre). Si hay libro oficial de abstracts: Novak A, Pardo de Santayana M, Prieto JM. 2006. Antioxidant activity as anti-inflammatory remedies. Res\u00famenes de la British Pharmaceutical Conference 2006 (Royal Pharmaceutical Society of Great Britain, Manchester, UK, 4-6 September) p. 23. Si los res\u00famenes fueron a su vez publicados en una revista se menciona S\u00d3LO a la revista como si fuera un art\u00edculo m\u00e1s. Novak A, Pardo de Santayana M, Prieto JM. 2006. Antioxidant activity Recursos electr\u00f3nicos Nota: Si hay que partir alguna direcci\u00f3n se recomienda hacerlo despu\u00e9s de una barra inclinada ATENCION: hoy existen mu chos otros tipos de dominios que no son http. Por ejemplo los hay https o ftp. Igualmente existe n muchos dominios que no son www, sino www2 u otros. Por tanto preste atenci\u00f3n a la direcci\u00f3n completa y no asuma que por defecto van a ser http o www. Duncan R. 2000. Nano-sized particles as \"nanomedicines\". http://www.mhra.gov.uk/home/idcplg?IdcService=GET_FILE&dDocName=con2022821&RevisionSelectionMethod=Latest . [Consultada el 6 de Octubre de 2006]. En caso de no haber un autor, o cuando no hay un responsable principal, se toma la instituci\u00f3n responsable como equivalente al autor, y en el texto se cita (CNN, 2000). CNN. Cuba's health care manages despite embargo. http://www.cnn.com/TRANSCRIPTS/0108/18/yh.00.ht ml [Consultada el 5 octubre de 2006]. Boletines o revistas on-line con ISSN, la fuente debe ser citada como cualquier otra revista. Prieto JM. 2005. El B\u00e1lsamo de Fierabr\u00e1s. BLACPMA 4(3):48-51. Importante NOTA sobre la citaci\u00f3n de p\u00e1ginas Web En estos d\u00edas se esta comprobando el creciente ABUSO de la citaci\u00f3n de paginas Web para av alar afirmaciones cient\u00edficas hechas por los autores. Resulta muy peligroso para su credibilidad como autor, y para la credibilidad de este Bolet\u00edn, citar informaci\u00f3n obtenida en p\u00e1ginas Web que no tengan ninguna entidad cient\u00edfic amente reconocida que se haga responsable de la susodicha informaci\u00f3n. Las p\u00e1ginas Web \"an\u00f3nimas\" Solo deben ser usadas en casos muy justificados y ante la absoluta ausencia de ninguna otra fuente primaria cient\u00edficamente reconocida. El Comit\u00e9 Editorial de esta revista realizar \u00e1 todo esfuerzo para eliminar el recurso f\u00e1cil a p\u00e1ginas Web pseudo-cient\u00edficas y desde luego los autores deben en todo caso dar una explicaci\u00f3n de porque han recurrido a este tipo de fuentes. Todo abuso ser\u00e1 motivo de rechazo para publicaci \u00f3n, incluso si este ya fue (err\u00f3neamente) aceptado por los revisores. Si se trata de boletines o revistas on-line con ISSN, la fuente debe ser citada como cualquier otra revista. Autoridad Final de La Editorial Los editores se reservan el derecho de corregir o alterar los manuscritos enviados para publicaci\u00f3n en BLACPMA. Este procedimiento se ejecutara en los casos en los que los manuscritos no se avengan a est\u00e1ndares cient\u00edficos generalmente aceptados o si el contenido es innecesariamente largo o poco claro. Estas alteraciones pueden ser requeridas directamente al autor y en todo caso retrasaran la publicaci\u00f3n del manuscrito. Gracias de antemano por sus contribuciones El comit\u00e9 editorial de BLACPMA Editorial Bol. Latinoam. Caribe Plant. Med. Aromat. Vol. 6 (4) 2007 88 Estimados lectores, A todos nosotros nos une la pasi\u00f3n por las plantas medicinales pero tambi\u00e9n la preocupaci\u00f3n por su futuro regulado y sostenible. BLACPMA pretende ser un foro de comunicaci\u00f3n, actualizaci\u00f3n y discusi\u00f3n de todos los profesionales implicados en el cultivo de plantas medicinales y la investigaci\u00f3n, desarrollo y producci\u00f3n de medicamentos herbarios. Por tanto es misi\u00f3n obligada de este su bolet\u00edn acometer, de vez en cuando, una auditoria de la situaci\u00f3n del sector. Para ello el comit\u00e9 editorial de BLACPMA ha decidido abordar la situaci\u00f3n actual de la regulaci\u00f3n de los medicamentos herbarios (o fitomedicinas) en forma de n\u00fameros monogr\u00e1ficos, para los cuales hemos invitado a autores de todo el mundo a explicar los \u00faltimos desarrollos reguladores en las distintas \u00e1reas geogr \u00e1ficas y econ\u00f3micas de su competencia. Para empezar en esta primera entrega se recoge la particular visi\u00f3n de las plantas medicinales de un referente mundial en el tema, Geoffrey Cordell, quien adem\u00e1s de Profesor Em\u00e9r ito de Farmacognosia en Chicago, es activo miembro del comit\u00e9 de este bolet\u00edn (Cordell, 2007). Un primer bloque trata de enmarcar el tema con una somera visi\u00f3n de los movimientos pasados y actuales a nivel regulador regional y global (Prieto, 2007) a lo cual sigue una presentaci\u00f3n de la situaci\u00f3n europea como primer ejemplo mundial de regulaci\u00f3n transnacional en materia de medicinas herbarias (Peschel, 2007a) y una discusi\u00f3n de las peculiaridades nacionales a la hora de implementar (\u00a1o no!) estas directivas (Peschel, 2007b). Los dos autores trabajamos en el Centro de Farmacognosia y Fitoterapia de la Universidad de Londres que ha tomado un papel leader en la organizaci\u00f3n de encuentros sobre la regulaci\u00f3n de Medicinas Tradicionales Herbarias Europeas (Heinrich, 2007). Dos art\u00edculos sobre la situaci\u00f3n reguladora de MH en Jamaica (Robertson, 2007) y Cuba (Ram\u00edrez et al., 2007) proveen una excelente perspectiva de la diversidad de aproximaciones normativas en la Regi\u00f3n del Caribe. Las autoras trabajan todas activamente en la regulaci\u00f3n de MH en sus respectivos pa\u00edses a nivel privado e institucional respectivamente. Para cerrar este n\u00famero, el Profesor Mukherjee, editor regional en Asia de Journal of Ethnopharmacology , y sus colaboradores nos explican como el subcontinente Indio trata de establecer un marco \u00fanico para la multitud de sistemas tradicionales que esta zona alberga as\u00ed como las miles de plantas medicinales y drogas minerales y animales que forman parte de los mismos . Es un buen ejemplo de lo complejo que puede llegar a ser poner orden y concierto en un campo tan rico y diverso como la medicina tradicional. En una pr\u00f3xima entrega trataremos de hablar de Sudam\u00e9rica y Centroam\u00e9rica, Norteam\u00e9rica (M\u00e9xico, Estados Unidos y Canad\u00e1), China y \u00c1frica. Esperamos que este en sus manos antes de Mayo pr\u00f3ximo. Aprovecho para invitarles a visitar nuestra p\u00e1gina Web, que acorde al cambio del bolet\u00edn ha crecido en complejidad. Ahora cuenta con servicios de b\u00fasqueda interna y descarga de separatas, entrega electr\u00f3nica de art\u00edculos para su publicaci\u00f3n, noticias y mucho m\u00e1s. Sin m\u00e1s pre\u00e1mbulo, les dejo con la esperanza de que encuentren \u00fatil e informa tivo todo este material que hemos preparado con nuestra mayor ilusi\u00f3n. Les saluda cordialmente, Dr. Jos\u00e9 Maria Prieto Coordinador del Especial Regulaci\u00f3n de Fitomedicamentos Editor Cient\u00edfico Jefe de BLACPMA Referencias Cordell GA. 2007. A vision for medicinal plants. BLACPMA 6(4): 89 - 91. Gonz\u00e1lez Ram\u00edrez M, Rem\u00ed rez D, Jacobo OL. 2007. Antecedentes y situaci\u00f3n reguladora de la medicina herbaria en Cuba. BLACPMA 6(4):118-124. Heinrich M. 2007. Future of UK herbal industry good as long as it adapts to new framework. Pharm. J . 278:286. Mukherjee PK, Ventakesh M, Ku mar V. 2007. An Overview on the Development in Regulation and Control of Medicinal and Aromatic Plants in the Indian System of Medicine. BLACPMA 6(4):129-136. Peschel W. 2007a. The Traditional Herbal Traditional Use Directive on the Herbal Product Markets in the United Kingdom, Germany and Spain. BLACPMA 6(4):112-117. Prieto JM. 2007. La regulaci\u00f3n global de los medicamentos herbarios. BLACPMA 6(4):92-101. Robertson \u00a9 2007 Los Autores Derechos de Publicaci\u00f3n \u00a9 2007 Bolet\u00edn Latinoamericano y del Ca ribe de Plantas Medicinales y Arom\u00e1ticas, 6 (4), 89 - 91 BLACPMA ISSN 0717 7917 Especial Regulaci\u00f3n Regulation of Phytomedicines A vision for medicinal plants [Una visi\u00f3n de las plantas medicinales] Geoffrey A. CORDELL University of Illinois at Chicago, Chicago, 2nd 2007 Abstract In the past few years, the author has written a number of artic les discussing a vision for the development of medicinal plants. This article will therefore present only a brief synopsis of some of the more sali ent features of those articles , o f four, clear, visions for the future of medicinal sustainability for medicinal th e regulatory affairs, pharmacogn osy, quality control, sustainability, global health care. Resumen En el pasado pocos a\u00f1os, el autor ha escr ito un cierto n\u00famero de art\u00edculos en los que discut\u00eda su visi\u00f3n de l desarrollo de la c iencia y regulaci\u00f3n de las plan tas medicinales. Este art\u00edculo pret ende hacer una s\u00edntesis de algunas de las caracter\u00edsticas m\u00e1s saliente s de esas visiones de los art\u00edculos, dando por resultado la pres entaci\u00f3n de cuatro claras y complementaria s visiones para el futuro de plantas med icinales: control de calidad realzado, sostenibilidad para las plantas medicinales, farmacognosia \"en una maleta\", y encontrar una \"voz f uerte\" en el campo de la pol\u00ed tica del cuidado m\u00e9dico global. Palabras clave: medicamentos herbarios, farmacognosia, regulaci\u00f3n, control de cali dad, desarrollo sostenible, cuidados m\u00e9dicos globales. In the past few years, the author has written a number of articles discussing a 2000; 2002; Cordell and Colvard, therefore present only a brief synopsis of some of the more salient features of resulting in the presentation of clear, coalescing visions for the future of medicinal plants in global health care. In \"A Still Forest Pool \" the venerated Thai monk, Ajahn Chah opined that \"If you are on the fifth step and you think that you are too high, you will never make it to the sixth step\". What I believe that he is saying, at many different levels, is there is always room for improvement, and don't be so complacent as to think that all is known that can be known, or that the best that can be done is being done. It is a philosophy that later came to be known a system was possible. In my view, as far as medicinal plants in public health care globally are concerned, we are just beginning to LOOK at the first step. Yes, it is a public health care issue, although in some countries it is not seen that way, and thus the paucity of effective local regulations based on science. A recent WHO survey showed that of the 192 countries surveyed only 53 had any form of regulations for traditional medicines, and for only 18% of the countries were medicinal plants included in the National Pharmacopoeia (WHO, 2002). Yet, at least 64% of the global population use medicinal plants as their primary form of health care (Farnsworth et al., 1985), and this percentage will rise steadily as the global population reaches 10 billion in the next 30 years. The lack of attention to the regulation of medicinal plants has occurred for a number of reasons, two of which are that: i) it is often assumed that these A vision for medicinal plants Cordell Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 90 medicinal agents, because th ey have been used for years, are safe (and thus don't need regulation), and ii) their supply is unlimited. These are both myths which need to be dispelled. As we think about the future of medicinal plants in health care, there are two burgeoning issues to be addressed: quality control and sustainability. For most of the countries of the world, pharmaceutical companies will not be provid ing the medicinal agents for local prevalent diseases, and for those diseases that are global, the drugs are likely to be very expensive. The question for these health care systems is how to address those issues, for optimum local health care. Medicinal plants, all over the world, are sold in a manner which has changed little in hundreds, may be thousands, of years. That is not something medicinal plant scientists should either be proud of, or condone. Quite the should be irate that their science is having such a limited impact on public health. From a public health perspective, what is a reasonable time frame to enhance quality control through the application of science and technology to traditional medicine? What can be done in 5 years, what in 10 years, and what in 15 years? Can a strategic health care plan which incrementally enhances the safety and effectiveness of traditional medicines for the benefit of the patient be developed? Where do we start to make these improvements? What are the sciences and the technologies that need to be involved? Are there enough scientists locally who are trained to do the work? prepared from a regulatory and science enforcement And of course, who will fund all those studies and protocol developments? This is not the place to be addressing in great detail all of the steps to achieve safe research programs begin with a literature evaluation. In the field of medicinal plant research, one of the highest priorities must be the determination of what is known and what questions need to be answered with a view to not duplicating previous research and wasting precious human and fiscal resources; ii) It is rare indeed that ethnomedical research is conducted with the scientist and clinician doing complex factories for secondary metabolites. A determination of the active principle(s) and their mechanism of action is critical for the development of systems for chemical and biological standardization; iv) Given the diversity of medicinal plant materials that are now in global commerce, it is critical that there be analytic standards in place to eliminate contaminants and adulterants which might pose a health hazard, are illegal, or which give a non-reproducible, false biological responses; v) Standardization of a given be based on a three-fold botanical, chemical, and biological standardization so that on a lot-to-lot basis there is a safety and efficacy guarantee for the patient. Botanical standardization based on PCR analysis, chemical standardization based on a known active principle (or principles), and biological standardization based on a cheap, relevant, and validated in vitro bioassay; vi) The age of a traditional medicine is important issue, but is rarely given. For each preparation there will need to be stability and safety studies, since it cannot be assumed that a preparation that has been used for hundreds of years is necessarily \"safe\". Neither can it be that the active principles, and therefore the clinical effectiveness of the product, will be stable for the shelf life of the product; vii) These botanical, appropriate clinical trial; viii) There the need to report register observed plant drug - drug interactions there is the need for sustainable development of a commercial medicinal plant. The forests and the mountains are already being depleted of medicinal plants as demand increases; and desirable medicinal plant endangered native little attention is being given to this aspect of medicinal plant development because the science to discern which plants are the most effective has not yet provided priorities for sustainable development. UN Millennium Ecosystem Assessment indicates (Millennium Ecosystem Assessment, 2005), we can no longer assume that the plant materials that are used as resources today will be there tomorrow. Consequently, and if the world is to have plant-based A vision for medicinal plants Cordell Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 91 medicinal agents in the future for a rapidly expanding global population, we must think of plant-based a fundamental health care requirement. For continued availability, we mu st therefore regard an a sustainable, renewable resource; a sustainable drug . For most people that is a new concept; many medicinal plant scientists do not think in those terms. New strategic thinking is also needed as to how medicinal plants are initially validated. We need to consider how to reverse the of collecting medicinal plant materials, identifying them macroscopically, drying them, bringing them back to the laboratory, extracting them, and testing the extracts for the steps just described, was taken to the field, and the preliminary determination regarding a level of interest for further experimentation made on site. Is there the potential to determine the authenticity and the chemical and biological potential of a medicinal plant in the field ? What are the implications for future studies of medicinal plants if that strategy can be successful? What are the range of technologies that need to be assembled for the botany, chemistry, and biology to be conducted? What are the nano technologies which can be applied to realize this? What areas of the required technologies need further development? Are there other barriers to the realization of goal? What would \"pharmacognosy in a suitcase\" look like? These are my three very clear visions for medicinal plants: enhanced quality control, sustainability for and a suitcase. They are significant regulatory, scientific, technological, economic and social challenges. They will take many years to accomplish, and many people to educate about the validity and absolute need for the approach. That brings me to my fourth vision... which is that medicinal plants, and their study for the future of the health of humankind, will find a strong \"voice\" at the political table of global health care for the sake of future generations. LITERATURE CITED Cordell, G.A. Out-of-Balance. Arkivoc vii:97-115. WHO. 2002. Traditional Medici nes. Secretariat Report. 111th Session 12 December 2002. agenda 1985. in Bull WHO 63, 965-981. Millennium Ecosystem Assessment, 2005. Ecosystems Human Autores Derechos de Publicaci\u00f3n \u00a9 2007 Bolet\u00edn Latinoamericano y del Ca ribe de Plantas Medicinales y Arom\u00e1ticas, 6 (4), 92 - 101 BLACPMA ISSN 0717 7917 Especial Regulaci\u00f3n Issue on Regulation of Phytomedicines La regulaci\u00f3n global de los medicamentos herbarios [The global regulation of herbal medicines] Jos\u00e9 Maria PRIETO Center for Pharmacognosy and Phytotherapy, Sc hool of Pharmacy, Un iversity of Square, WC1N 1AX London, United Kingdom *Contacto: jose.prieto@pharmacy.ac.uk Recibido el 1 de Noviem bre de 2007; Aceptado el 3 de Noviembre de 2007 Abstract This paper gives an overview on the regiona l and global regulatory efforts towards a homogenization of the normative about herb al medicines. The pioneering work of the WHO and the recent implementation of the first transnational directive on herbal medicine s in Europe have laid the legal and scientific foundations to help a fast implementation of transn ational regulations el sewhere. The most a dvanced regional frameworks are those of Latin America and the Asiatic eas t. China has started a process of to faci litate the globalisation of its traditional medicinal system. Africa is work ing towards the regulation of th e traditional medicines as a p revious step to their transnational regulation. If a global regulation for herbal medicines is far away, several organisations already st arted this process by introducing this subject into the agenda of the periodic meetings of national re gulatory agencies all herbal medicines, regulatory affairs. Resumen Se pretende presentar una visi\u00f3n conjunta de los esfuerzos region ales y globales para homogeneiz ar las normativas relativas a l a regulaci\u00f3n de medicamentos herbarios. El impulso inicial dado por los trabajos de la OMS y el ejemplo de la primera regulaci\u00f3n trasnaciona l, en la forma de la Directiva de Medicinas Tradicionales Europeas, han sentado las bases documentales ci ent\u00edficas y legales para ayudar a una r\u00e1pida implementaci\u00f3n de medidas trasnacionales en otros continentes. La implementaci\u00f3n de distintos consensos regionales sobre esta m ateria esta muy avanzada en Latinoam\u00e9rica y el Este Asi\u00e1tico. China ha em prendido un camino de implementaci \u00f3n de normativas que le permitan la globalizaci\u00f3n de su sistema de medicina tradicional. \u00c1frica trabaj a intensamente en la regulaci\u00f3n a nivel nacional de las medic inas tradicionales como un paso previo a su regulaci\u00f3n transnacional. Sin bien una regulaci\u00f3n global ta rdar\u00e1 en conseguirse, diverso s organismos ya han emprendido este camino en form a de encuentros regulares entre agen cias reguladoras de todo el mundo. Palabras clave: Globalizaci\u00f3n, regulaciones trasna cionales, medicamentos herbarios, regulaci\u00f3n. INTRODUCCION Las medicinas herbarias (MH), o si se prefiere fitomedicinas, est\u00e1n mas que nunca en el ojo regulador de naciones, organizaciones trasnacionales y entes internacionales. En casi todo el mundo las legislaciones nacionales se encuentran bajo una doble presi\u00f3n: la de un p\u00fablico que demanda mayor calidad en los productos, y la de los responsables de salud p\u00fablica que exigen mayor seguridad. Las grandes industrias del sector tienen diferentes posturas dependiendo del marco en que tradicionalmente se han movido: pasividad si gozan de mercados protegidos y af\u00e1n regulador en espacios econ\u00f3micos abiertos a la competencia, sin olvidar que muchas ven en todo ello una oportunidad de reducir la competencia de las peque\u00f1as compa\u00f1\u00edas que no podr\u00e1n afrontar los altos costes derivados de la elevaci\u00f3n de los remedios herbarios a la categor\u00eda de 'medicamento'. Hay que resaltar el hecho de que el concepto de medicamentos herbarios esta destinado a situarse dentro de una l\u00ednea 'blanda' de registraci\u00f3n, donde se exige una calidad garantizada pero no una eficacia probada cient\u00edficamente. El factor clave desencadenante del vendaval regulador ha sido la exitosa globalizaci\u00f3n de las medicinas tradicionales y complementarias (MT/MC). Hoy en d\u00eda se consumen productos procedentes de la Medicina Tradicional China (MTC) o Ayurveda o europea o sudamericana e incluso africana en casi todos lo s pa\u00edses desarrollados, generando una demanda creciente del mercado a nivel mundial. Aqu\u00ed es donde resalta por su ausencia una regulaci\u00f3n internacionalmente homog\u00e9nea: en los pa\u00edses de origen hay generalmente falta de Regulaci\u00f3n global de los medicamentos herbarios Prieto informaci\u00f3n sobre el productor, y adem\u00e1s no existe comunicaci\u00f3n entre las agencias reguladoras nacionales de pa\u00edses exportadores e importadores, todo ello creando una constante fuente de problemas para los servicios aduaneros y sanitarios en todo el mundo. Muchos pa\u00edses han comenzado ya la regulaci\u00f3n de sus mercados nacionales de MH mediante enmienda de sus leyes. La mayor\u00eda de ellas datan de los a\u00f1os sesenta y setenta y entonces casi ninguna contemplaba la categor\u00eda de MH. Otros pa\u00edses no parecen tener mayor preocupaci\u00f3n por establecer una categor\u00eda aparte para lo que hasta ahora se comercializa principalmente como suplemento alimentario, EE.UU. por ejemplo. Existen numerosos desarrollos de regulaci\u00f3n de medicamentos a niveles subregionales y regionales, algunos ligados a la creaci\u00f3n de espacios econ\u00f3micos comunes. Sin embargo el nivel de actividad reguladora en el campo de los MH dentro de cada una de ellas var\u00eda considerablemente. Entre los cuales destacan: Association of South-East Asian EU in 2004 European Union (EU) Gulf Cooperation Council (GCC) International Conference on Harmonisation (ICH) International Conference of Drug Regulatory Authorities (ICDRA) MERCOSUR (Southern Common Market) Pan American on Drug Regulatory Harmonization (PANDRH) Southern African Development Community (SADC) Cada una de las seis regiones de la OMS Los principales problemas que afrontan las autoridades a la hora de regular el sector de MH son la falta de datos cient\u00edficos, la falta de mecanismos efectivos de control, y la falta de educaci\u00f3n, formaci\u00f3n y especializaci\u00f3n del personal relacionado con la producci\u00f3n, distribuci\u00f3n, prescripci\u00f3n, uso y seguimiento del uso de MH (Zhang, 2006). LA OMS COMO FUENTE REGULADORA GLOBAL Tras el reconocimiento por parte de la OMS del valor de la medicina tradicional como fuente de salud y de biodiversidad en la C onferencia de Alma Ata de 1979 (OMS-UICN-WWF, 1993; OMS, 2002), se han venido financiando grupos de trabajo internacionales y regionales, as\u00ed como proyectos locales, para estudiar y fundamentar su uso regulado (WHO, 2001, 2005), la redacci\u00f3n de monograf\u00edas de control de calidad (WHO, 1998), de buenas pr\u00e1cticas agr\u00edcolas (GAP) (OMS, 2003), de buenas practicas de producci\u00f3n (GMP), de normas para asegurar la seguridad de los productos herbarios (WHO, 2004a), y de estrategias para su correcto uso en los sistemas de salud primarios (WHO, 2004b). Muchos pa\u00edses en v\u00edas de desarrollo han podido regular las medicinas herbarias en sus respectivos territorios nacionales bas\u00e1ndose en este cuerpo documentario, lo cual hubiese sido imposible desarrollar \u00fanicamente a nivel local. De hecho la necesidad del impulso de la OMS hoy en d\u00eda es aun alt\u00edsima, con solo un m\u00ednimo de pa\u00edses realmente autosuficientes para regularse como muestra la Figura 1 (Zhang, 2006). Figura 1. Dependencia de la OMS en cuanto a regulaci\u00f3n de MH (Zhang, 2006). 836870676650 444847504455 4753912 0 1 02 03 04 05 06 07 08 09 0InformacionSeguridadInvestigacionBases de datosRegulacionReuniones N. de paises Totalmente dependientes Parcialmente dependientes Independientes Leyenda: Reuniones (Congresos globales sobre regulaci\u00f3n); Regulaci\u00f3n (Talleres sobre regula ci\u00f3n de MH); Bases de Datos (Necesidad de bases de datos con informaci\u00f3n sobre MH); Investigaci\u00f3n (Gu\u00edas generales de investigaci\u00f3n de la eficacia de MH); Seguridad (Talleres sobre se guimiento de la seguridad de MH); Informaci\u00f3n (Necesidad de reuniones para intercambio de informaci\u00f3n sobre asuntos de regulaci\u00f3n) Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 93 Regulaci\u00f3n global de los medicamentos herbarios Prieto La OMS realizo dentro de este contexto un informe sobre el estado de cada una de las legislaciones nacionales de 141 pa\u00edses sobre MT/MCA (WHO, 2004c, 2005). El resultado fue que el 65% de los pa\u00edses consultados dispon\u00edan de regulaci\u00f3n de TM/CAM y el 42% est\u00e1n en el proceso de regulaci\u00f3n. La evoluci\u00f3n en los \u00faltimos tiempos puede observarse en la Figura 2. Figura 2 : Numero de pa\u00edses con legislaci\u00f3n Nacional sobre regulaci\u00f3n de MH o TM/CAM (WHO, 2004; 2005). Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 94 14182325334053697883 0102030405060708090 Before 1986 1986 - 1987 1988 - 1989 1990 - 1991 1992 - 1993 1994 - 1995 1996 - 1997 1998 - 1999 2000 - 2001 2002 - 2003Numero acumulativo de Paises REGULACION TRASNACIONAL EN AMERICA Se est\u00e1n llevando a cabo distintas iniciativas regionales y continentales para llegar a una homogenizaci\u00f3n de categor\u00edas y caracter\u00edsticas de los distintos productos herbales de consumo humano en Am\u00e9rica. Por un lado la Organizaci\u00f3n Panamericana de Salud (OPS o PAHO) auspicia encuentros regulares entre los responsables reguladores de los distintos pa\u00edses del continente. Por otro lado existen m\u00faltiples iniciativas regionales a cargo de asociaciones de libre comercio como MERCOSUR, ANDEAN, y CARICOM por ejemplo. Mercosur MERCOSUR cuenta como miembros de pleno derecho Argentina, Brasil, Paraguay, Uruguay y Venezuela, mientras que Bolivia, Chile, Colombia, Ecuador y Per\u00fa son estados asociados y M\u00e9xico y Nicaragua estados observadores. En este espacio com\u00fan econ\u00f3mico se vienen realizando diversas reuniones bajo el nombre de MERCOFITO donde se de baten todos aquellos aspectos relacionados con la incorporaci\u00f3n de fitomedicamentos en los sistemas de salud, el desarrollo de polos productivos regionales a trav\u00e9s de la incorporaci\u00f3n de cultivos de plantas medicinales, la posibilidad de crear una Farmacopea del Mercosur para este tipo de productos, mostrar los trabajos cient\u00edficos as\u00ed como coordinar ensayos cl\u00ednicos en la regi\u00f3n, sin olvidar la impl ementaci\u00f3n de estrategias para concienciar a la pobl aci\u00f3n sobre el uso racional de este recurso, y debatir pol\u00edticas regionales en com\u00fan para la ense\u00f1anza en foros acad\u00e9micos de la Fitomedicina en consona ncia con los enunciados propuestos por la Organizaci\u00f3n Mundial de la Salud. Para una descripci\u00f3n mas detallada de sus objetivos ver Cuadro 1) (Mercofito, 2007). Mercofito esta compuesto por diversos entes tanto gubernamentales como privados, incluyendo Ministerios de Salud del Brasil, Argentina y Paraguay, agencias nacionales como la Agencia Nacional de Vigilancia Sanitaria de Brasil (ANVISA), instituciones acad\u00e9micas (Universidad Nacional de Asunci\u00f3n) y profesionales (Asociaci\u00f3n Argentina de Fitomedicina) as\u00ed como diversas organizaciones locales como por ejemplo el Comit\u00e9 Gestor de Plantas Medicinales de Itaip\u00fa Binacional, F\u00f3rum por la Vida - Proyecto Plantas Vivas de la Asamblea Legislativa de Rio Grande do Sul (ALERGS), ONG Agraci\u00f3n, Asociaci\u00f3n del Centro Integrado de Educaci\u00f3n, Naturaleza y Salud (ACIENS-Brasil). Caribe La regi\u00f3n caribe\u00f1a tiene plena conciencia de que sus productores y ciudadanos en general est\u00e1n poco o nada capacitados para beneficiarse de sus recursos locales debido a una falta tanto de visi\u00f3n como de inversi\u00f3n. Los principales problemas econ\u00f3micos que impactan negativamente sobr e la industria herbolaria caribe\u00f1a son: intercambio con el extranjero limitado, poca tasa de empleo y poca capacitaci\u00f3n de la industria local, pobreza, poca especializaci\u00f3n en la mano de obra, ausencia de colaboraci\u00f3n entre sectores econ\u00f3micos clave y falta de estructuras para el transporte de mercanc\u00edas entre las Islas de la regi\u00f3n (Robertson, 2007a). La situaci\u00f3n a nivel regional es muy complicada. Cuba lleva a cabo una intensiva implementaci\u00f3n de los medicamentos herbales en su sistema de salud para paliar las consecuencias de una dif\u00edcil situaci\u00f3n internacional. Entre el resto de Islas de habla hispana no existe ninguna actividad intergubernamental sobre el tema digno de menci\u00f3n aparte de la llevada a cabo dentro de los foros regionales de la OMS u OPS. Regulaci\u00f3n global de los medicamentos herbarios Prieto Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 95 Cuadro 1. Propuestas y objetivos de MERCOFITO. Elaboraci\u00f3n de una Farmacopea Herb aria del Mercosur, que permita el rescate del conocimiento tradicional sumado al aporte del conocimiento cient\u00edfico. Incorporaci\u00f3n de la ense\u00f1anza de la Fitoterapia dentro de las disciplinas obligat orias de grado y posgrado en las carreras universitarias del \u00e1rea de la salud, as\u00ed co mo la ense\u00f1anza de la misma como asignatura dentro de los planes de formaci\u00f3n entre los agentes de atenci\u00f3n primaria de la salud. La propuesta de ense\u00f1anza sobre plantas medicinales comprender\u00e1 tambi\u00e9n las \u00e1reas de ense\u00f1anza universitaria de las carreras agra rias, sociales, ambientales y antropol\u00f3gicas . Se debatir\u00e1, adem \u00e1s, crear una Univer sidad del Mercosur donde puedan desarrollarse carreras relacionadas con las \u00e1reas antes descritas. Creaci\u00f3n de la Red Mercofito - una red de cooperaci\u00f3n t\u00e9cnico-cient\u00edfica - in tegrada por gobiernos, unive rsidades, laboratorios nacionales, asociaciones profesionales, funda ciones y empresas con compromiso social pertenecientes al Mercosur, cuyo objetivo ser\u00e1 priorizar la cadena productiva y el desarrollo socioecon\u00f3 mico regional a trav\u00e9s del cu ltivo de plantas medicinales y elaboraci\u00f3n de medicamentos fitoter\u00e1picos. A su vez, se propone crear un Fondo de Investigaci\u00f3n, Producci\u00f3n y Formaci\u00f3n de Recursos Humanos, por medio de los di ferentes integrantes de la red. Elaboraci\u00f3n de una pol\u00edtica en com\u00fan consensuada sobre plantas medicinales y medicamentos fitoter\u00e1picos entre los pa\u00edses integrantes del Mercosur (socios activos y adherentes). Se propone la creaci\u00f3n de un Ente Coordinador sobre Plantas Medicinales para cada pa\u00eds miembro (a excepci\u00f3n de aque llos pa\u00edses que ya lo tengan). Asimismo, lo s diferentes Minister ios de Salud de cada pa\u00eds establecer\u00e1n las medidas necesarias pa ra la incorporaci\u00f3n de medicamentos fitoter\u00e1 picos en los Vadem\u00e9cums de Remedios, as\u00ed como las pol\u00edticas necesarias que tiendan a incorporar este tipo de recurso en los centros de Atenci\u00f3n Primaria de la Salud. Integraci\u00f3n entre los Ministerios de Relacione s Exteriores de los pa\u00edses miembros del Mercosur, para establecer pautas o criter ios de trabajo para la toma de decisiones pol\u00edticas inherentes a las experiencias de la cadena productiva de plantas medicinales y medicamentos fitoter\u00e1picos para el Mercosur. Tareas de coordinaci\u00f3n y di\u00e1logo entre los integrantes del III\u00b0 Mercofito y de PLANSUR con las C\u00e1maras empresariales de fitomedicamentos y las entidades que nuclean al sector agrotecnol\u00f3gico de cultivo de especies medicinales, de manera tal que permitan fortalecer la cadena productiv a agroexportadora de estos productos. Rescate y reconocimiento del patrimonio et nom\u00e9dico correspondiente a los pueblos originarios de los pa\u00edses integrantes del Mercosur. Dentro de dicha pauta se propone incorporar a las dis tintas etnias al sector producti vo para el desarrollo de polos agr\u00edcolas elaboradores de materias primas a partir de plantas medicinales. Elaboraci\u00f3n de un Manual sobre Plantas Me dicinales y Medicamentos Fitoter\u00e1picos para el Mercosur, el cual contemplar\u00e1 informaci\u00f3n de uso tradicional, validaci\u00f3n cien t\u00edfica de dichos usos, asp ectos toxicol\u00f3gicos, gal\u00e9nicos, bot\u00e1nicos, indicaciones de uso y agrotecnolog\u00eda de cultivo de las especies incorporadas. Establecimiento de un Comit\u00e9 de Expertos que permita la optimizaci\u00f3n de la cadena productiva, por medio de la normatizaci\u00f3n de procedimientos que aseguren la calidad de la materia prima, la correcta selecci\u00f3n de especies de acuerdo a las necesidades epidemiol\u00f3gicas y la preservaci\u00f3n y manutenci\u00f3n del germoplasma. Generar los marcos regulatorios adecuados para armonizar aspectos legislativos, asistenciales, t\u00e9cnico-cient\u00edficos, comerciales y sobre propiedad industrial (Ley de Patentes). Las islas angl\u00f3fonas son mas activas y ya est\u00e1n organizadas y sensibilizadas sobre el tema. Como primer paso se realizo un estudio sobre las especies caribe\u00f1as de mayor importancia industrial para una primera fase de explotaci\u00f3n financiado por el CTA (Centre for Technical Agriculture) en colaboraci\u00f3n con Holanda y el IICA (Inter-American Institute for Cooperation on Agriculture). Por otro lado, se han creado dos asociaciones de car\u00e1cter no gubernamental para propulsar la coordinaci\u00f3n a nivel regional: la Caribbean Association of Researchers & Herbal Practitioners (CARAPA) y Caribbean Herbal Business Association (CHBA). CARAPA, que se creo en 1998, esta formada por herbolarios, cient\u00edficos y personal sanitario y pretende integrar el sistema tradicional en el sistema convencional de salud, c on una especial preocupaci\u00f3n respeto a eficacia, estudios cl\u00ednicos y seguridad de su uso ( CARAPA , web site). Por su lado la CHBA pretende llegar a crear un grupo industrial operacional regional ( Industrial Cluster Operation) para lo cual organiza talleres de trabajo para el control de calidad con la ayuda del CDE (Center for Development Enterprise) bajo el auspicio del ICS-UNIDO. A nivel legislativo se trabaja en la enmienda del actual marco legal para ponerlo a la altura de los tiempos y sacar de la desregulaci\u00f3n al sector (Roberton, 2007a). Iniciativas Latinoamericanas Redes de trabajo internacionales como CYTED y RIPROFITO financian estudios de Legislaci\u00f3n sobre Fitof\u00e1rmacos en Am\u00e9rica Latina como parte de sus Subprogramas, as\u00ed como libros de monograf\u00edas de plantas espec\u00edficamente latinoamericanas (Gupta, 2003; Garc\u00eda y C\u00e1ceres, 2000). Las conclusiones de dichos trabajos reflejan la enorme heterogeneidad en la terminolog\u00eda empleada para describir las especialidades herbarias, as\u00ed como faltas importantes en el sentido de que a menudo no hay una clara definici\u00f3n de la materia prima y del principio activo, poca uniformidad en los re quisitos de registro y Regulaci\u00f3n global de los medicamentos herbarios Prieto Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 96 posterior comercializaci\u00f3n as\u00ed como enormes diferencias entre las normas de calidad, seguridad y eficacia. Para resolver es tos desfases se trabaja en: Promover y fortalecer el intercambio de informaci\u00f3n sobre Plantas Medicinales; Pr omover la garant\u00eda de la calidad, seguridad y eficacia de Plantas Medicinales en las Am\u00e9ricas, incluyendo el desarrollo de un programa de vigilancia y control; Desarrollar propuestas armonizadas en el tema de Plantas Medicinales: Apoyar a los pa\u00edses en la implementaci\u00f3n de las mismas promoviendo programas y actividades de educaci\u00f3n para proveedores de servicios de salud, consumidores y p\u00fablico en general (Gupta, 2003). Iniciativas americanas de armonizaci\u00f3n de sistemas ind\u00edgenas y convencionales La armonizaci\u00f3n del espacio americano esta siendo facilitado por una iniciativa que en principio persegu\u00eda documentar y reconocer oficialmente los sistemas de medicina y terapia ind\u00edgenas, asign\u00e1ndoles un puesto dentro de los respectivos sistemas de salud, lo que se ha denominado \"Proceso de armonizaci\u00f3n de sistemas ind\u00edgenas y convencionales\". Desde 1993, la OPS ha trabajado en esta Iniciativa de Salud de los pueblos Ind\u00edgenas. Primariamente ten\u00eda el objetivo de mejorar la salud y bienestar de dichas comunidades culturales. Sin embargo este trabajo esta derivando en la homogenizaci\u00f3n de pol\u00edticas regionales para regular la medicina tradicional y con ella los medicamentos herbarios. En 1997 se culmino la primera etapa de este proyecto con las resoluciones CD37.R5 y CD40.R6 que apelan a los estados miembros a velar por soluciones sostenibles que tengan en cuenta las barreras geogr\u00e1ficas, econ\u00f3micas y culturales de los grupos mas vulnerables, incluyendo los ind\u00edgenas. En 1999 la OPS/OMS organizo un grupo de trabajo en Medicinas tradicionales complementarias y alternativas como actividad conjunta de la Divisi\u00f3n de desarrollo de Sistemas y servicios (HSP) y el departamento de pol\u00edticas de drogas y medicinas esenciales. Los participantes recomendaron promover actividades para apoyar los conocimientos de medicina tradicional, complementaria y alternativa e identificar estrategias para contribuir a la organizaci\u00f3n y creaci\u00f3n de sistemas de salud adecuados en toda Am\u00e9rica que reconozcan expl\u00edcitamente la contribuci\u00f3n a la salud p\u00fablica de las medicinas ind\u00edgenas. Para ello apel aron a la coordinaci\u00f3n entre OPS/OMS y entidades de reconocido prestigio en medicinas tradicionales como la Universidad de Illinois en Chicago (UIC), EE.UU., y el Centro de medicina complementaria y alternativa del instituto nacional de salud (NCCAM-NIH). Durante 2000-2001 se desarrollo una segunda fase del proyecto que focalizaba en la medicinas herbarias, Ind\u00edgenas y las Tradicionales, Alternativas y Complementarias, con el objetivo de promover e integrar la medicina ind\u00edgena en los sistemas de salud primaria. Ahora se trata de continuar los trabajos en estas \u00e1reas espec\u00edficas dentro del marco de una Estrategia Global para la Me dicina Tradicional, cuya culminaci\u00f3n fue el 'global meeting' que tuvo lugar en Ottawa, Canad\u00e1 (IRCH, 2005). Todo este esfuerzo esta teniendo ya una traducci\u00f3n concreta a nivel de pol\u00edticas nacionales. Argentina y Chile han consentido en la formaci\u00f3n de personal especializado en medicina Mapuche y la creaci\u00f3n de dispensarios de medicina tradicional Mapuche f\u00edsicamente situados en los centros de salud p\u00fablicos (Linares Calvo, 2007; Ylarri, 2007; Orrego Guerrero, 2002). Ecuador y Panam\u00e1 podr \u00edan seguirlos en breve ya que llevaron a cabo estudios previos de documentaci\u00f3n de la contribuci\u00f3n de las medicinas y terapias ind\u00edgenas en la atenci\u00f3n de salud primaria y se dise\u00f1aron instrumentos y metodolog\u00edas para entender la seguridad y eficacia de dichos sistemas tradicionales con la ayuda de la OPS (PAHO, 2002). Iniciativas panamericanas La Reuni\u00f3n del grupo de trabajo de la PAHO realizada en Curitiba (Brasil) (PAHO, 2006) hizo propuestas para avanzar en la homogenizaci\u00f3n del sector fitoter\u00e1pico a nivel continental: a. Propuesta de definici\u00f3n de Plantas Medicinales a ser adoptada por todos los pa\u00edses; b. Propuesta armonizada de requisitos para plantas medicinales basada en criterios cient\u00edficos; c. Necesidad de asegurar la calidad, eficacia y seguridad de las plantas medicinales; d. Promoci\u00f3n y educaci\u00f3n para proscriptores y consumidores. Sin embargo el peso de la actividad reguladora lo lleva sobre todo la Pan American Network for Drug Regulatory Armonizaci\u00f3n (PANDRH) que se dedica a identificar problemas en el desarrollo de la armonizaci\u00f3n global de regulaci\u00f3n de todo tipo de medicamentos, incluidos los MH para facilitar lo que definen como \"hemispheric drug regulatory harmonization\". Esto se c onsigue siguiendo de cerca los desarrollos de grupos subregionales y recomendando estrategias y acciones. La PANDRH incluye reguladores de la Andean, Caricom, Mercosur, NAFTA, SICA, as\u00ed como de la Industria y la Regulaci\u00f3n global de los medicamentos herbarios Prieto Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 97 Academia. La regulaci\u00f3n hom og\u00e9nea futura de los MH se incluyo dentro de las prioridades identificadas tras las tres conferencias realizadas en Washington (1997, 1999 y 2002) lo que sin duda refleja la importancia de estos productos en los mercados americanos (Molz\u00f3n, 2003). REGULACI\u00d3N TRASNACIONAL EN AFRICA Los intentos de regulaci\u00f3n pan-africanos empezaron en 1985 con la redacci\u00f3n de una Farmacopea Africana en dos vol\u00famenes bajo los auspicios de la Organization of African Unity Scientific Technical Research Commission (OAU/STRC) (CAMH, 2005). Con este cuerpo documental mas los producidos por la OMS, la OAU tomo la decisi\u00f3n en Julio de 2001 de declarar la primera d\u00e9cada del s. XXI como la \"D\u00e9cada de la Medicina Tradicional\" (Min isters of Health of the WHO African Region. 2007). El Foro Africano para el Desarrollo (ADF) es una iniciativa conducida por la Comisi\u00f3n Econ\u00f3mica Africana (ECA) para impulsar una agenda conducida por organismos netamente Africanos sobre programas espec\u00edficos como la \"Declaraci\u00f3n de Abuja acerca de HIV/AIDS, Tuberculosis y otras enfermedades infecciosas\" (African Development Forum, 2000). Las tareas a afrontar son establecer pautas para la formulaci\u00f3n, puesta en pr\u00e1ctica, supervisi\u00f3n y evaluaci\u00f3n de un marco jur\u00eddico para la pr\u00e1ctica de la medicina tradicional en los diferentes pa\u00edses; establecer un c\u00f3digo \u00e9tico para su implementaci\u00f3n en el sistema de salud; crear un marco regional para el registro de medicinas tradicionales y sobre todo un marco regulador para la pr otecci\u00f3n de los derechos de propiedad intelectual y del conocimiento ind\u00edgena de medicinas en la regi\u00f3n del africana de la OMS (Kofi- Tsekpo, 2004). La consecuci\u00f3n de los obj etivos previstos de la sensibilizaci\u00f3n de la d\u00e9cada (2001 - 2010) y de la popularizaci\u00f3n de la medicina tradicional en todos los Estados miembros (CAMH, 2005) proveer\u00e1 de facto las bases para una regulaci\u00f3n continental de las MH. Aparte existen ciertas iniciativas a nivel sub-africano como la Southern African Development Community (SADC) que entre otras tareas coordina una parte del esfuerzo com\u00fan de diversos pa\u00edses sudafricanos en frenar el SIDA d\u00e1ndole a la medicina tradicional un papel relevante. Cuadro 2: Objetivos de la D\u00e9cada Africana de la MT. 1. Adopci\u00f3n de pol\u00edticas nacionales sobre medicina tradicional. 2. Establecimiento de marcos jur\u00eddicos y de la legislaci\u00f3n necesaria sobre medicina tradicional en todos los Estados miembros. 3. Adopci\u00f3n por parte de los Estados miembro de las herramientas de WHO/AFRO y de EMRO para institucionalizar la medicina tradicional en los sistemas de la salud. 4. Establecimiento de estructuras permanentes en los ministerios de la salud para poner en ejecuci\u00f3n programas de medicina tradicional en todos los Estados miembros. 5. Inauguraci\u00f3n de mesas nacionales de la medicina tradicional para regular su pr\u00e1ctica y sus productos. 6. Adopci\u00f3n de pol\u00edticas nacionales para la protecci\u00f3n del acceso a la biodiversidad y del conocimiento m\u00e9dico tradicional (ley modelo del AU). 7. Establecimiento de centros de colaboraci\u00f3n de excelencia/OMS para la inve stigaci\u00f3n y el desarrollo de las medicinas tradicionales usadas para el tratamiento de las enfermedades prioritarias. 8. Instituci\u00f3n en todos los Estados miembros de una semana nacional de la medicina tradicional. 9. Creaci\u00f3n de el ambiente pol\u00edtico, econ\u00f3mico y regulador necesario para permitir el desarrollo de la producci\u00f3n local y la conservaci\u00f3n de plantas medicinales y arom\u00e1ticas. 10. Promoci\u00f3n de la investigaci\u00f3n precl\u00ednica y evaluaci\u00f3n cl\u00ednica, desarrollo, produ cci\u00f3n local y comercializaci\u00f3n de medicinas tradicionales estandardizadas. 11. Registro de medicinas tradicionales estandardizadas en la lista esencial nacional de medicinas tradicionales. 12. Prescripci\u00f3n, uso racional y supervisi\u00f3n de medicinas tradicionales estandardizadas en sistemas de cuidado m\u00e9dico p\u00fablicos y privados. REGULACI\u00d3N TRASNACIONAL EN ASIA Oriente Pr\u00f3ximo En noviembre de 2001, las autoridades reguladoras de los Estados miembros del WHO del Este de la Regi\u00f3n Mediterr\u00e1nea se reunieron en El Cairo para discutir la regulaci\u00f3n regional de las medicinas herbarias. Las medicinas tradicionales son ampliamente utilizadas en esta regi\u00f3n pero la mayor parte de estos pa\u00edses no tiene ninguna ley sobre el control de calidad de medicinas herbarias. Algunos pa\u00edses, tales como la Rep\u00fablica Isl\u00e1mica de Ir\u00e1n, la Rep\u00fablica \u00c1rabe Siria y de Yemen, tienen monograf\u00edas para las medi cinas herbarias. Las preocupaciones de las autoridades reguladoras en la regi\u00f3n se refieren generalmente m\u00e1s a la falta de seguridad en las MH que a su eficacia. Hay una gran necesidad de personal expert o para controlar a los Regulaci\u00f3n global de los medicamentos herbarios Prieto Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 98 productores de medicinas herbarias. Por tanto las prioridades regionales en el \u00e1rea de medicinas herbarias incluyen el entrenamiento de los profesionales de salud, la educaci\u00f3n p\u00fablica, el fomento de intercambio de informaci\u00f3n y la formaci\u00f3n de expertos nacionales para registrar MH y auditar en GMP, sin olvidar la necesidad de referencias para las plantas medicinales traducidas a los lenguajes de la regi\u00f3n y la creaci\u00f3n de una estrategia de protecci\u00f3n de los recursos vegetales. (Ren y Keller, 2002) ASEAN Los pa\u00edses de la Association of South-East Asian Nations (ASEAN) que son Brunei, Darussalam, Indonesia, Malasia, Filipinas, Singapur, Tailanda y VietNam (y en un futuro pr\u00f3ximo Camboya, Laos y Myanmar) han creado un espacio com\u00fan econ\u00f3mico y est\u00e1n apostando fuertemente por la constituci\u00f3n de un polo biotecnol\u00f3gico regional estableciendo colaboraciones estrat\u00e9gicas con otros espacios econ\u00f3micos, empezando por Europa, lo cual se ha materializado en el ECAP (EC-ASEAN Intellectual Property Rights Co-operation Programme). La ASEAN comenz\u00f3 su esfuerzo integrador ya en in 1979. En la practica los primeros proyectos en el sector de medicamentos empezaron a implementarse hacia 1982, con la ayuda de WHO, UNDP y JPMA. Dentro de las m\u00faltiples actividades de homogenizaci\u00f3n de sus merc ados farmac\u00e9uticos, la estandardizaci\u00f3n, control de calidad y uso de MH en la ASEAN es parte los objetivos generales del programa llamado ASEAN TCAC Pharmaceuticals que persigue reforzar el se ctor farmac\u00e9utico mediante el cumplimiento de las recomendaciones de la OMS/DAP y conseguir en la regi\u00f3n una autosuficiencia en recursos humanos especializados. El uso de MH en todos los pa\u00edses ASEAN se estimula por la necesidad de incrementar la cobertura de salud y por la de aprovechar los recursos locales en una regi\u00f3n en la que el uso de MH es tan extendido e intenso. Para ello se constituyo el Traditional Medicines & Health Supplements Product Working Group (TMHS - PWG). Su primera prioridad ha sido la de obtener materiales de referencia como premisa para establecer las normativas y directrices de calidad, as\u00ed como para atacar los problemas actuales de la regi\u00f3n en materia de medicina tradicional que consisten principalmente en la proliferaci\u00f3n de productos adulterados o fals ificados, confusi\u00f3n de nombres, combinaciones de plantas con potencial efecto toxico, contaminaciones de metales pesados y uso no sostenible de plantas inmaduras. Los resultados del esfuerzo com\u00fan en ASEAN han sido la creaci\u00f3n de un manual de cultivo, producci\u00f3n y uso de MH en la salud prim aria, la concretizaci\u00f3n de acuerdos de elaboraci\u00f3n de MH siguiendo GMP, la publicaci\u00f3n de un primer volumen de 36 monograf\u00edas de MH medicinales de inter\u00e9s regional, a lo que se suma la de otras 14 monograf\u00edas de drogas crudas y la creaci\u00f3n de mas de 40 herbarios a disposici\u00f3n de las autoridades locales. Los lideres de los pa\u00edses miembros de ASEAN acordaron que en 2010 las MH y suplementos diet\u00e9ticos deben estar regulados en su espacio com\u00fan (ASEAN, 2007a; 2007b; Zhang, 2006). China - Europa China quiere globalizar su sistema tradicional y asegurar que las pol\u00edticas reguladoras en marcha en Europa y otros pa\u00edses no le cierren el paso a sus exportaciones de plantas medicinales. Para ello en 2005 ha actualizado la edici \u00f3n de su farmacopea bajo la supervisi\u00f3n de expertos europeos con el objetivo de acercar las normas de calidad chinas a los par\u00e1metros occidentales que hacen hincapi\u00e9 en la determinaci\u00f3n de marcadores qu\u00edmicos y sustancias bioactivas. Este aspecto marca la evoluci\u00f3n de la aproximaci\u00f3n china cl\u00e1sica a la calidad del material vegetal que se basaba mas en la identificaci\u00f3n del material y su procesamiento principalmente. Por otro lado China y la Uni\u00f3n Europea han establecido un canal privilegiado para la regulaci\u00f3n de las drogas vegetales usadas en la medicina tradicional china (MTC) con vistas a la homologaci\u00f3n de las monograf\u00edas de la farmacop ea china que permitan su importaci\u00f3n, venta y dispensaci\u00f3n en Europa. Esta voluntad ha cristalizado en un reciente encuentro al m\u00e1ximo nivel en Roma (Ministry of Science and technology of RRPP China, Ministero Della Sanita de Italia, Directorate General for Research EU, 2007) y provee un segundo espacio com\u00fan Sino-Europeo para los medicamentos herbarios. Hong Kong, que siempre ha sido el punto de enlace entre China y el Occi dente, se sit\u00faa velozmente en este papel en cuanto a la globalizaci\u00f3n de la MTC se refiere. En esa ciudad se han creando distintas organizaciones para potenciar este proceso. Ejemplos son la Modernized Chinese Medicine International Association ( MCMIA ) formada por cient\u00edficos y profesionales de la industria y que pretende poseer un fuerte car\u00e1cter multi-disciplinar. El Consortium for Regulaci\u00f3n global de los medicamentos herbarios Prieto Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 99 Globalization of Chinese Medicine ( CGCM ) creado en diciembre de 2003 agrupa a 19 instituciones de todo el mundo y pretende avanzar en las metodolog\u00edas requeridas para el control de calidad de los MH aplicando las mas modernas tecnolog\u00edas, crear una base de datos con informaci\u00f3n completa sobre MH chinos y coordinar ensayos cl\u00ednicos de acorde a normas internacionalmente validas. REGULACION TRASNACIONAL EN EL AREA DEL PACIFICO Western Pacific Regional Forum for the Harmonization of Herbal Medicines (FHH) La necesidad prioritaria de este grupo, compuesto por Australia, China, Japon, Republica de Korea, Singapur, Viet Nam y Hong Kong (SAR China) es el de regular la MTC, que es usada activamente en estos pa\u00edses con las mismas pautas filos\u00f3ficas que en China. Sin embargo existe una disparidad de normas de calidad que impiden el comercio fluido de MH en la regi\u00f3n (Zhang, 2006). La FHH es un foro t\u00e9cnico en el que participan las autoridades reguladoras de los pa\u00edses miembros. Se redactan documentos de con senso t\u00e9cnico y cient\u00edfico en materia de seguridad, eficacia y calidad de MH, evitando la duplicaci\u00f3n del esfuerzo regulador, creando las bases de un uso sostenible de recursos valiosos y resolviendo la fa lta de normativa en \u00e1reas importantes de la salud publica. REGULACION TRASNACIONAL EN EUROPA La Uni\u00f3n Europea, recientemente ampliada a 27 miembros, y un total de 470 millones de consumidores, provee un espacio altamente regulado para la armonizaci\u00f3n del mercado. La Agencia Europea del Medicamento (EMEA) que fue creada como organizaci\u00f3n reguladora trasnacional de la Uni\u00f3n en materia de medicamentos, ha desenvuelto su papel de manera tan exitosa que la OMS la ha tomado como modelo de sistema de gesti\u00f3n de informaci\u00f3n y la promueve como referencia en todos sus foros regionales (Lepakhin, 2004). La regulaci\u00f3n inexorable de todos y cada uno de los productos europeos ha llegado a los productos herbarios que, desde 2004, est\u00e1n en la cuenta atr\u00e1s de su regulaci\u00f3n obligatoria como Medicamentos Tradicionales Herbarios o a su degradaci\u00f3n a la categor\u00eda de suplemento alim entario a partir de 2011. Para mas detalles l\u00e9ase el art\u00edculo escrito por Peschel (2007) en este mismo n\u00famero. Cumplido este objetivo de regular la medicina herbaria \"occidental\", Europa se ha embarcado en la creaci\u00f3n de canales privilegiados con China y ASEAN para la futura integraci\u00f3n de la MTC y otros productos del Sudeste Asi\u00e1tico en el mercado eur opeo (Ministry of Science and technology of RRPP China, Ministero Della Sanita de Italia, Directorate ASEAN, 2007a, 2007b. REGULACION GLOBAL: SITUACION ACTUAL Existen algunos movimientos de car\u00e1cter m\u00e1s o menos mundial que pretenden la coordinaci\u00f3n de los entes reguladores de medicinas. Una de ellas es la International Conference of Drug Regulatory Authorities (ICDRA), que desde 1980 sostiene reuniones bianuales. Es una iniciativa de la OMS para proveer un foro \u00fanico par a las autoridades reguladoras de todos sus estados miembros, determinando las prioridades de acci\u00f3n a nivel nacional e internacional de regulaci\u00f3n de medicinas, vacunas, biomedicinas y medicamentos herbarios (WHO, 2007; Lepakhin, 2004). Los objetivos de ICDRA son definir criterios y normas de calidad para medicinas herbales, alimentos funcionales y suplementos diet\u00e9ticos entre todos los estados miembros y junto a la OMS, la cual continuara a desarrollar gu\u00edas de calidad, seguridad y eficacia de MH y sus combinaciones. La OMS tambi\u00e9n pretende impulsar un programa de monitorizaci\u00f3n de uso y seguridad de MH, iniciativa que debe ser fortalecida e implementada pos los estados miembros. La OMS tambi\u00e9n seguir\u00e1 proporcionando apoyos a estados miembros, especialmente en v\u00edas de desarrollo, para desarrollar programas de informaci\u00f3n sobre el adecuado uso de MH por parte del p\u00fablico. A nivel gubernamental, la OMS provee asesoramiento en la educaci\u00f3n del personal sanitario. La ICDRA coordinara toda la inform aci\u00f3n generada a trav\u00e9s de estos programas. (WHO, 2007; Lepakhin, 2004)). Otra iniciativa global de la OMS es la llamada Cooperaci\u00f3n Internacional en materia de Reglamentaci\u00f3n de los Medicamentos Herbarios (IRCH), cuyo objetivo principal es el de fomentar y facilitar el uso seguro de los medicamentos herbarios a nivel mundial, a trav\u00e9s de iniciativas regionales, del intercambio de informaci\u00f3n y del di\u00e1logo (ICDRA 2006). Esta aun en su fase inicial y ahora se centra en la creaci\u00f3n de una red de intercambio de informaci\u00f3n sobre aspectos t\u00e9cnicos de la regulaci\u00f3n de MH mediante comunicaci\u00f3n electr\u00f3nica a diario entre los Regulaci\u00f3n global de los medicamentos herbarios Prieto Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 100 \"Information Focal Point\" nominados por cada miembro del IRCH y la organizaci\u00f3n de reuniones anuales bajo el nombre de la \"Global Strategy for Traditional Medicine\", cuyo grupo de trabajo acord\u00f3 desarrollar una segunda serie de monograf\u00edas de Plantas medicinales en sus reuniones de Ottawa (Canad\u00e1) en 2005 (IRCH, 2005) y Beijing (China) en 2006, donde asistieron autoridades reguladoras de cada uno de los grupos de las seis regiones/sub- regiones de la OMS as\u00ed co mo grupos de cooperaci\u00f3n internacional incluyendo FHH, PANDRH, the European Herbal Medicines Committee, the ASEAN Group on Traditional Medicines and Health Supplements (TMHSPWG) y el parlamento Latino Americano (PARLATINO) (Zhang, 2006). En contraposici\u00f3n a estos movimientos de globalizaci\u00f3n \"populista\" mediante foros y organizaciones cuya pertenencia esta abierta a todos los pa\u00edses, y dotados de organizaci\u00f3n interna flexible se sit\u00faan los modelos \"corporativos\" de armonizaci\u00f3n global de medicinas, como la ICH. La opci\u00f3n corporativa esta caracterizada por una estructura altamente formal y definida, cuya pertenencia es restringida, que establece objetivos y fechas de entrega de resultados (Molz\u00f3n, 2003). La ICH es una organizaci\u00f3n internacional en la que participan pa\u00edses europeos, Jap\u00f3n y EEUU as\u00ed como el Ministry of Health, Labour and Welfare de Japon (MHLW), la European Federation of Pharmaceutical Industries Associations (EFPIA), Japan Pharmaceutical Manufacturers Association (JPMA), Food and Drud Administration (FDA) y la America's Pharmaceutical Research Companies (PhRMA) para el desarrollo de requerimientos t\u00e9cnicos homog\u00e9neos para productos medicinales. Aunque las normativas desarrolladas en este foro so lo aplican a los pa\u00edses miembros, es evidente que el peso de los mismos en el mercado marcan las pautas a seguir a nivel global. Existe un Comit\u00e9 dedicado a MH dentro de esta organizaci\u00f3n, aunque no existen aun desarrollos tangibles. LA AMENAZA BIOTERRORISTA COMO FUERZA REGULADORA Hechos totalmente al\u00edenos al mundo de las plantas medicinales han impulsado una regulaci\u00f3n global de facto para las plantas medicinales. Los atentados del 11 de septiembre de 2001 dieron lugar a la aprobaci\u00f3n del acta de bioterrorismo de la FDA ( regulation 21 CFR Part 1, Subpart I), de acuerdo a la cual todos los productores de suplementos alimentarios (categor\u00eda que en EEUU corresponde a los MH) que quieran registrarse en esta agencia deben cumplir las GMP. China ha sido una de las mas afectadas debido al alto volumen de especialidades herbarias exportadas desde este pa\u00eds (Chan, 2003; FDA, 2003). CONCLUSIONES Se ha iniciado un movimiento a escala planetaria de globalizaci\u00f3n de los distintos sistemas de medicina tradicionales as\u00ed como de homogenizaci\u00f3n del mercado de medicamentos herbales y plantas medicinales. El impulso inicial dado por los trabajos de la OMS y el ejemplo de la primera regulaci\u00f3n trasnacional, en la forma de la Directiva de Medicinas Tradicionales Europeas, han sentado las bases documentales y legales pa ra ayudar a una r\u00e1pida implementaci\u00f3n de medidas trasnacionales en otros continentes. Podemos pronosticar que en la pr\u00f3xima d\u00e9cada la implementaci\u00f3n de distintos consensos regionales sobre esta materia, siendo los m\u00e1s avanzados aquellos que se desarrollan dentro de espacios econ\u00f3micos comunes, como MERCOSUR o ASEAN. \u00c1frica ha comenzado por la creaci\u00f3n de un marco estable a nivel continental para la medicina tradicional como paso previo a la regulaci\u00f3n trasnacional. Tanto \u00c1frica como ASEAN se han marcado el 2010 para cumplir estas perspectivas. Si bien una regulaci\u00f3n global tardara en conseguirse, diversos organismos ya han emprendido este camino en forma de encuentros regulares entre agencias reguladoras de todo el mundo. BIBLIOGRAF\u00cdA African Development Forum. 2000. The Abuja framework for action for the fight against HIV/AIDS, Tuberculosis and other related infectious diseases the AU decade of Traditional medicine (2001-2010): implementation of the Lusaka summit of heads of State and Government (AHG/DEC.164 (XXXVII). 2nd Ordinary session of the conference of African ministers of health (2) Gaborone, Botswana, 10 - 14 October. Chan R. 2003. Challenges in the globalization of Chinese herbal medicine. Second International Conference & Exhibition of the Modernization of Chinese Medicine & Health Products (ICMCM) - Hong-Kong, Republica Popular China, 14-18 August. Regulaci\u00f3n global de los medicamentos herbarios Prieto Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 101 FDA. 2003. The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (the Bioterrorism Act). Garc\u00eda M, C\u00e1ceres A. 2000. Legislaci\u00f3n en Iberoam\u00e9rica sobre Fitof\u00e1rmacos y Productos Naturales . Ed. CYTED-LEBi-ASACIMSS-EU, Costa Rica. Gupta MP. 2003. Legislaci\u00f3n sobre Productos Herbarios en Centro Am\u00e9rica y los Pa\u00edses Andinos. Presentaci\u00f3n en ICS-UNIDO Training Course, Panam\u00e1 City, Panama. 21-25 de the Working group on regulatory cooperation on herbal medicines. Ottawa, Canada, 28 to 30 November. Kofi-Tsekpo M. 2004. Ins titutionalization of African Traditional Medicine in Health Care Systems in Africa. African J Health Sci. 11(1-2):1-2. Lepakhin VK. 16 - 19 February, Madrid, Spain Linares Calvo X. 2007. Imposici\u00f3n de manos en un hospital . La Nacion (Argentina) 10 de agosto. MERCOFITO. 2007. Res\u00famenes del Congreso. Organizado por la Comisi\u00f3n de Salud y Deporte, Comisi\u00f3n de Acci\u00f3n Social y Salud P\u00fablica y la Asociaci\u00f3n Argentina de Fitomedicina) Buenos Aires CF, Republica Argentina, 14 y 15 de Junio. Ministers of Health of the WHO African Region. 2007. Declaration on Traditional Medicine , fifty-seventh session of the Regional Committee for Africa Brazzaville,. Republic of the Congo, 31st August. Ministry of Science and technology of RRPP China, Ministero Della Sanita de Italia, Directorate General for Research EU, 2007. Handbook for Sino-European conference on tradicional chinese medicine. Roma, Italia, 27 de Junio. Molzon JA. 2003. Models for Regional Cooperation In Drug Regulation. The 2003 Symposium on APEC, Network of Pharmaceutical Regulatory Science. Taipei, Taiwan, November 18. OMS, UICN, WWF. 1993. Direct rices sobre conservaci\u00f3n de plantas medicinales. UICN, Gland, Suiza. OMS. 2002. Estrategias de la OMS sobre la Medicina Tradicional 2002-2005. WHO/EDM/TRM/2002.1, Ginebra, Suiza, OMS. 2003. Directrices de la OMS sobre buenas pr\u00e1cticas agr\u00edcolas y de recolecci\u00f3n (BPAR) de plantas medicinales. Ediciones de la OMS, Ginebra, Suiza. Orrego Guerrero M. 2002. Validando la Medicina Tradicional. Ecoportal 20 de marzo de 2002. PAHO. 2002. Traditional, Complementary and Alternative Medicines and Therapies: Evaluation Plan of Work 2000-2001 and Plan of Work 2002-2003 . Washington, D.C. US. PAHO, 2006. Actas de la II Reuni\u00f3n del grupo de trabajo de plantas medicinales. Curitiba, Brasil, 29-31 Marzo. Peschel. 2007. The Traditional Herbal Medicine Directive European regulatory framework for Herbal Products. BLACPMA Ren K (moderators). 2002. Tenth International Regulatory 24-27 Wealth of Database Policy and Regulation of TM/CAM and Herbal Medicines including information from 141 countries. Editions of the OMS, Geneva, Switzerland. WHO. 2005. Summary report of the global survey on national policy on traditional medicine and regulation of herbal medicines. Editions of the OMS, Geneva, Switzerland. WHO. 1998. Quality Control Me thods for Medicinal Plants Materials. Editions of the OMS, Geneva, Switzerland. WHO. 2001. Legal Status of Traditional Medicine and Complementary/Alternative Medicine: A Worldwide Review. WHO/EDM/TRM/2001.2. Editions of the OMS, Geneva, Switzerland. WHO. 2004a. WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems, Editions of the OMS, Geneva, Switzerland. WHO. 2004b. WHO Guidelines on Developing Consumer Information on Use of Traditional, Complementary and Alternat ive Medicine. Editions of the OMS, Geneva, Switzerland. WHO. 2005. National Policy on Traditional Medicine and Regulation of Herbal Medicine . Report of WHO Global Survey. Editions of the OMS, Geneva, Switzerland. WHO. 2007. International Conference of Drug Regulatory Authorities (ICDRA) , WWW. Ylarri PA. 2007. sistema formal. DyN 11.08.2007 URL [U ltimo acceso 1/11/07] Zhang Cooperation on Proper Use of Traditional Medicine. Oral Presentation International Regulatory Cooperation on regulation of Herbal medicines (IRCH) 29 March, Brazil. \u00a9 2007 Los Autores Derechos de Publicaci\u00f3n \u00a9 2007 Bolet\u00edn Latinoamericano y del Ca ribe de Plantas Medicinales y Arom\u00e1ticas, 6 (4), 102 - 111 BLACPMA ISSN 0717 7917 Especial Regulaci\u00f3n Regulation of Herbal the European regulatory framework for Products [La Directiva Europea de Medicamentos Herbales Tradic ionales en el contexto Europeo de Productos Herbales] Wieland PESCHEL Centre for Pharmacognosy and 1AX London, United Kingdom *Contacto: wieland.peschel@pharmacy.ac.uk Recibido el 13 de Abril de 2007; Aceptado el 19 de Julio de 2007 Abstract A series of new European guidelines specifically for herbal medi cine has been generated over the last 10 years, which is embedded in the general harmonisation process of medicines regulation within the European Union. Although not generally welcomed, the need for quality and safety standards has been backed by a number way of marketing authorisation under consideration of national peculiarities. T his paper gives an introduction to the current five regulatory pathways and the eligible guidance for herbal medicine Traditional European Medicine, he rbal medicine regulation, safety, quality. Resumen En el ultimo decenio se han generado una se rie de guias europeas sobre medicamentos herbarios que se enmarcan en un proceso de armonizacion general del Mercado farmaceutico en la Union Europea. Aunque no siempre bien recibidas, la aparicion de efectos ad versos ha veces afectando a varios paises miembros simultaneamente, han creado necesidad de reforzar las normas de seguridad y calidad A. Es en este contexto que aparece la Directiva Europea (2004/24/EC) para la registraci\u00f3n simplificada de productos medicinales herbarios tra dicionales ha establecido una nueva via de arm onizacion del mercado considerando las peculiarid ades nacionales existent es. Este articulo pret ende introducir al lector en las cinco diferentes maneras de registro y la eligibilidad pa ra los medicamentos herbarios en Europa. Palabras clave: Medicinas Tradicinales Europeas, Me dicamentos herbales, regul of Abbreviations: BfArM: for Drugs and Medical Devices for Herbal Medicinal Products HMPWP: Herbal Well European Directive Peschel Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 103 1 THE CHALLENGE TO REGULATE HERBAL MEDICINAL PRODUCTS IN EUROPE Herbal products for health purposes have been used traditionally in all European countries, most of them now member of the European Union with all legal consequences. In the past, the way of market access and legal handling is almost as heterogeneous as the botanical and ethnopharmacological patchwork of the plants behind these products. The herbal medicinal market in Europe is currently affected by substantial changes of the regulatory environment. Efforts driven by the general intention to harmonise the regulation of medicinal products, food and other consumer goods at centralised European level. On the other side, authorities are particularly reacting to a changing European market and cases of adverse events linked to the consumption of herbal medicine, mainly the Chinese one [Stickel et al. 2003, Singh 2005, Nortier & Vahherweghem 2002]. The first group is characterised by the increasing scientific knowledge about side effects/interactions, but also by the growing public awareness including the media and competitors from the synthetic drug market that herbal medicine is not in general harmless [Elvin- Lewis, 2005]. The second group of \"imports\" is accompanied by a series of new challenges which in this extent were not rele vant for a more national \"pure\" European market so far. This refers to the increasing numbers of poor or wrong declarations and adulteration with metals, caused a of fatal outcomes. But also often and derived products can face a standardised [Gruenwald et al. 2003]. However, in order to differentiate the good, the bad the ugly, each consumer, manufacturer, regul ator and journalist which differ from synthetic MP: the heterogeneity variability, sources), the part used, type of preparation, manufacturing process), and the lack of accurate quality/safety data for often non-standardised low price products. All points require a careful analysis of any adverse event in particular when it comes to the transfer of data and some kind of \"c lan liability\" for products, which are not comparable. Furthermore can stated certain toxicity is regarded safe\" paradigm and regulation level worldwide certain overreaction. Herbal medicinal products are classical borderline products and term herbal medicinal product as such an umbrella term for a complex variety of products which have only in common to be of herbal origin and to be health related [Barnes 2003]. The very natural grey area between food and medicine, cosmetics and medicine etc. will always cause demarcation problems, even more when the very competitive food/cosmetic market tends to use health claims for marketing reasons. Understandably, small manufacturers of medicine try to avoid the considerable burden of medicinal law and customers prefer low price products if no risks are associated them. Therefore, the priority of medication or nutrition/ cosmetic use, the of also Table 1). is getting when the miscellaneous mixture of herbal products itself and all kind of combinations can cause the allocation of the same plant/product into various categories, not only by the intention of use but by the concentration and daily dose or only the type of package declaration on otherwise preparation. Beyond this primary herbal medicinal Traditional medicinal products join now the category and the marketing licensing process to go (Table 1). The complexity of the when quality/safety shall apply the traditions, Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 104 the regulatory handling (National peculiarities, borderline to food EU includes countries which traditionally deal with HP predominantly as medicinal product (Germany, Austria, Denmark), as \"traditional\" medicinal product (France, Spain, Sweden) or exempted from medicine law mostly registered as food (UK, Benelux, Portugal). Usually all member states accept various categories for herbal medicine from the legal point of view and few efforts are made to clarify grey areas and to suit action to the word [Benzi & Ceci 1997]. 2 EUROPEAN Union is tackling these uncertainties of the herbal sector for a decade now and has established a decent framework of guidelines which at least in part will harmonise the European market (Table 2). However, national peculiarities will remain and a comparable degree as for synthetic products with single chemical entities will probably never new traditional directive art. 2003/63/EC) as alternativ e between food (almost no health claims possible) and full marketing authorisation including the upgrading EMEA based herbal medicinal products working party to (HMPC) guideline specific guidelines of different level directive problems (e.g. EMEA/HMPC/CHMP/CVMP/287539/2005) (for an overview see Table 2). This package has to be understood as amendment to general medicine law focusing on the peculiarities of means for instance, if the full quality part 2.1 of the common technical document is required, it includes also the GMP conform sometimes not manageable hurdle) for small manufacturers. On the other hand,, the time and effort of quality control, stability tests and declaration of expertise and between safety and appropriate expenditure. Before the European Commission, and the EMEA/HMPC became the key players for the regulation of the herbal market, there has been other organisations facing the acclamation of the with of the European (Ph Member States and 20 observers such as the American FDA and the WHO. Its role is to harmonise the quality standards for use by healthcare professionals. The Ph Eur is the only official pharmacopoeia in Europe to be used for international trade and it is mandatory in European marketing authorisation dossiers in 36 member states. The group of experts from the Ph Eur is proposed by all national authorities and appointed by the Ph Eur commission. The ESCOP was a voluntary organisation in order to the scientifically The first national data based approach of major dimension was the German so called Commission E within the Federal Health Institute. This means, on the basis of national monographs there was already for most at the European level. These monographs usually represent the state of the art and provide the basis for well established use Subsequently ESCOP and Ph Eur monographs are now for the WEU and THMP monographs established successively European gold of stified product diversity. Likewise, other herbal medicine specific topics have not only there national, but also international anticipators. The Good Agricultural Practice guideline for herbal starting materials (246816/2005) for instance has been built on Peschel Bol. Latinoam. Caribe Plant. Aromaticas 6 (4) 2007 105 EUROPAM (The European Herb Growers Association, first version 1998), and the WWF Traffic network, starting together with other organisations 1993 with the Guidelines on the Conservation of Medicinal Plants. The division of legal, administrative and enforcement tasks and responsibilities between the European Directorate General, Pharmaceuticals) the EMEA CHMP, etc) and national authorities of the member states (e.g. MHRA in UK, BfArM in Germany, AGEMED in Spain) is not always as transparent for non-insiders as it should be. Furthermore between direct EU regulations, EU directives to be implemented by the member states into national law, and pure national law will cause some confusion for any HMP manufacturer. However, by now and in the near future, the herbal sector practically will mainly deal with national authorities as either for a national MA or for the MRP procedure. The adoption and legibility of European law is task of the national regulating authority and their advice is fundamental for the final decisions. A good communication basis with the national authority for an expertise driven exchange of opinions is the key for pragmatic solutions in this virgin soil of pan-European HMP regulation. There are only a few experiences yet with the new regulations; hence their practicability has to be shown in the future. There are only 8 products in three member states registered under the new traditional use legislation so far. 79 applications in 12 MS are reported [Woodfield 2007]. Both statistics reflect and TU, the law interpretation of national authorities, the proof of traditional use, the some MS [Roether 2006, Krisper 2007]. BIBLIOGRAPHIC APPLICATION (WEU) According to 2001/83/EC as for any other medicinal product HMP MA can be obtained under central procedure (CP), decentralised (DCP) or mutual of national (MRP). However, many herbal medicinal products are still licensed on a national basis due to the differences in national practices with respect to such products. HMP for which sufficient evidence is available to support the quality, safety and efficacy of the product must apply for a full MA. Applications with full supporting data, as usual for so called new chemical entities (NCE), are rare; more common is to go for the \"well-established use\" provision of a bibliographic application according to Article 10 of Directive 2001/83/EC on the basis of published literature (see alsoTable 1). In the broadest sense are these generic applications, whereby the comparator referred to is not an already established product after data protection time but accepted scientific core-data. This means also, will usually not be accepted as THMP, as efficacy/safety data are available and have not to be replaced by the proof of traditional use. But differences of the product and authority practice in the member states will cause doubling e.g. a Harpagophytum product is licensed as traditional medicine authorities due to sufficient safety and efficacy data. By now, only one HMP is listed for the CP (a Boswellia extract), dossier with the monograph. such monographs have been established, other appropriate monographs, publications or data may be referred to. The process of monograph and list establishment Herbal European Directive Peschel Bol. Latinoam. Plant. Med. Aromaticas Vol. 6 (4) 2007 106 Table 1. General overview on EU regulation types for health related herbal products Category Subcategory Legal ba sis Main 2003/63/EC no individual but HMP actions of the HMPC is to facilitate the use of the mutual recognition procedure for herbal medicinal products. This means that to the THMP (see section below), the HMPC has only supporting functions for the fully responsible CHMP in case of full dossier and WEU applications. This is bei ng done in part by updating the guidance documents relating to bibliographical as a means of facilitating the assessment of safety and efficacy.Considering the still missing experience with CP and DCP, here only some key points for a bibliographic application via MRP are outlined: In general the format for an application for MA must be based on the Common Technical Document (CTD), consisting of 4 and 5) are replaced by references to published scientific literature. The content of modules 1 (includes SPC), 2 (administrative data) and 3 (quality) is equivalent to any other the Notice to Applicants and not have to demonstrate individually compliance with the criteria for WEU and safety, but will still have to meet the normal requirements regarding quality. This means first of all that the principles and guidelines of herbal medicinal products (EC Volume Annex 18 of the GMP guide relating to requirements for active ingredients be considered, while factors concerned with the primary production and processing of the herbal drug is covered by the already mentioned good agricultural Plant. Med. Aromaticas Vol. 6 (4) 2007 107 Table 2. Herbal medicine specific guidelines within the EU to the the European parliament and of of 31 March 2004 amending ... Directive 2001/83/EC on the Community code relating to products for human use EMEA/HMPC/261344/2005 Concept paper on CTD for traditional herbal medicinal products Guideline on Declaration Herbal Substances and Herbal Preparations in Herbal Medicinal Products/Traditiona l Herbal Medicinal Products in the SPC3 EMEA/HMPC/107436/2005 a CPMP/QWP/2819/00 Guideline Medicinal Products/Traditional Medicinal Products EMEA/HMPC/125562/06 Reflection Paper on the use of Fumigants EMEA/HMPC/CHMP/CVMP/58222/06 Concept Paper on Quality of Combination Herbal Medicinal Products/Traditional Herbal Medicinal Products EMEA/HMPC/246816/2005 Guideline on Good Agricultural and Collection Practice (GACP) for starting materials on herbal origin Safety + Pharmacovigilance EMEA/HMPC/ 104613/2005 Guideline on the assessment of clinical efficacy in the preparation of monographs/lists for traditional herbal medicinal products/substances/preparations risks with d in preparations of Angelica archangelica L. EMEA/HMPC/413271/06 Concept paper on the development of a guideline on the assessment of genotoxic constituents on Non-Clinical Documentation Herbal Medicinal Products in Applications for Marketing Authorisation (Bibliographical and Mixed Applications) and in Applications for Simplified Registration EMEA/HMPC/246736/05 Public Statement on products containing asarone EMEA/HMPC/138381/05 Public Statement on the risk s the use of herbal products containing Aristolochia species EMEA/HMPC/138386/05 Public herbal medicinal products containing estragole EMEA/HMPC/138363/05 Public Statement on methyleugenol Efficacy EMEA/HMPC/104613/05 Guideline on the assessment and efficacy in the preparation of community herbal monographs for well-established and of community herbal monographs/entries list Guideline Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 108 4. TRADITIONAL HERBAL MEDICINAL PRODUCTS The so called \"Traditional Use Directive\" 2004/24/EC had to be implemented by member states (MS) by 30/10/2005. This has been realised by most MS with some delay (except Check Republic, Ireland, Netherlands, and Norway as associated MS). However, difficulties in the transition and establishment of enforcement rules still remain in 15 MS [EFPIA Draft Document: Status of Implementation of the European Union Pharmaceutical Legislation at Member State Level, 16/05/2007]. A transitional period is given for traditional herbal medicinal products which were already on the market on the 30/04/2004 (date of entry into force of Directive 2004/24/EC). This allows sufficient time for regulators/manufacturers to adapt the new requirements and to accumulate evidence of usage in the EU of existing products. By 2011 all old/new herbal medi cinal products will have to licensed/registered in order to stay on the market. 2004/24/EC can apply when applicants provide evidence relating to (Table allows a derogation from the standard efficacy requirements when justified by the product's safety profile, i.e. safe traditional use for a minimum of 30 years thereof 15 within the EU. To prove this, bibliographic or expert evidence will be by the traditional use, a bibliographic review of safety data together with an expert report will be required as it is usual for the WEU (see section above). In critical products it can happen that the authority request own data necessary for accessing the safety of the product. This may apply specifically in response to actual developments or recent as happened with the interaction potential of various HP. When relating to a corresponding comparable\") product, active ingredients, the intended purpose, the route of administration have to be the same or similar, and equivalent strength and posology are expected as well. The law allows only that the number/quantity of ingredients may have been reduced during the qualifying period of traditional use. The practical interpretation of the legal terms \"comparable\", \"similar\", \"equivalent\" and the usefulness of combinations and removal of single ingredients will cause some discussion and vary possibly between the regulators of further restrictions for registrations as the medical practitioner, whether for diagnostic are excluded THMP restricted to medicines that are taken or are for external use or inhalation. The to food is vitamins or minerals may be possible, where there is evidence of safety and where the action of the nutrient is ancillary to that of the herbal active ingredients.\" given a marketing authorisation on the basis of supporting safety and efficacy data (e.g ., using publis hed papers) will procedure. Likewise homeopathic medicines will be The content of application for a traditional use registration application will based on to full MA ap plications, which includes the use of core data by positive lists and herb active ingredients used as active substances. There will be a requirement to a Manufacturer's to the requirements of Articles 16b and 16c many of the other provisions of Directive 2001/83/EC will apply for OF HOMOEOPATHIC other exemption from normal MA procedures as outlined in Peschel Bol. Latinoam. Plant. 6 (4) 2007 109 Table 3. Relevant monograph systems as ba sis for bibliographic applicati ons of THMP and HMP (WEU and mixed applications). The total number monographs includes as well as general monographs (e .g. herbal extracts) Organisation Included species Total number of monographs Comment Commission E 190 380 Elaborated in the 90s by an Expert committee formed by the German government within the Federal Health Institute (BGA) ESCOP 73 80 Following the work of the Commission E the ESCOP Scientific Committee (initially funded by the of HMP, monographs are updated/recognized by the EMEA WHO 54 58 Compiled by 120 experts in more than 50 countries and published in 2 volumes (1999, 2002), rather secondary status in Europe Ph Eur 126 only quality st andard in Europe to be used for international trade. Constant ly updated; last June 2007 EMEA/HMPC WEU 8 (3 drafts) 9 (3 drafts) EMEA/HMPC are released for public consultation on the fo r 3 months. Further in preparation: 8 monographs where th traditional medicine, where th e efficacy is supposed to be plausible based on long-standing use and experience and some examples of ingredients instead of tincture not comparable concentration replacement of ingredients in combinations external 30 years traditional use, including at least 15 within the EU case by case geogr. non-European but politically European areas such as French Guyana all new EU member states case by case when less than 30/15 years (but other conditions can apply = but not National decision) prove not to be harmful the specified given Plant. (4) 2007 110 2001/83/EC. A simplified registration procedure for those used officially in homeopathic medicinal contain a number of principles.\" These may include non-herbal starting materials, which are not yet considered for the traditional use directive. does not allow indications data Often registration under the scheme is compulsory only in respect of products new to national markets. In order to qualify for registration under the simplified procedure, the products must be for oral or external use. This includes all methods of administration with the exception of injections. In general homoeopathic MP must be sufficiently dilute to guarantee their safety. Of course companies also have the option obtaining a homoeopathic remedies, provided that the regulatory requirements for can be satisfied. When a \"traditionally used\" homoeopathic stock further dilution is the manufacturer may have the decision between simplified regulation under the traditional use or the homoeopathic category, which in general are exempted to each other (see above). In both cases, no efficacy data have to accompany quality (including shelf life tests) and safety data. Differences labelling and marketing ( the WEU will contribute considerably to the case by of the appropriate regulatory strategy. to is predominantly by rules. UK for of Homeopathic in be granted. However, each other under the umbrella of the Homeopathic Medicinal Product Working Group (HMPWG), which informal meetings first started in 1999. The participants of HMPWG are assessors and regulatory experts from the National Competent Authorities, as well as representatives from the EC, Ph Eur, EMEA and WHO. The group was formalised by the Head s of Medicines Agencies (HMA) in 2004. The HMPWG is a forum of exchange of regulatory and scientific expertise as well as elaboration and and expertise and on request regarding procedural, regulatory and scientific issues arising from the MRP/DCP. It was started because there was a clear need for a European solution for the regulation of homeopathic MP due to the particular characteristics of this therapeutic system. 6. HERBAL PRODUCTS OUTSIDE countries the of HP were classified as food supplements, which facilitated market access without provision of detailed quality and safety data. Herbal remedies equally to minera ls or vitamins have a classical \"dual-use\" - character, where nutrition/diet paralleled by health promoting/ therapeutic purposes. The a herbal in the borderline is still dominantly national decision according to case by case studies based on law and tradition. But similarly to the Traditional Use Directive, the market of the single member states will be influenced by the pan-European food legislation in the future. The opinion\" will consider the possible risk, the pharmacological characteristic due to current scientific knowledge, the degree to which the consumer is familiar with the product and the way in which the product is used. For many manufacturers of herbal products, it is getting more and more important to deal with the legal differentiation between medicine and food (respective cosmetics) which includes questions like: Which constituents are legal in food or cosmetics? Do they have any phamacological effect? Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 111 Which effects has the demarcation on Which nutrition declarations have to be stated on package and leaflet? How to deal with health claims? Step by step the EU will also harmonise the food law in terms of food supplements and their safety. A first definition of foodstuffs has been introduced with regulation 178/2002/EC 2002/46/EC contains definition for food supplements for first time. Primarily there were between food supplements and medicinal products. Furthermore, the directive covers only vitamins and minerals. future, the may as fatty acids, fibre, and plant extracts. activities by EFSA and EC. A helpful overview on current European food legislation in is Gulati & Ottaway (2006). 7 CONCLUSIONS The manufacturer of a herbal medicinal product has now five main regulatory pathways for marketing in Europe. Within medicine law a full application, a well established use application or simplified registration as either traditional herbal medicinal product or as homoeopathic medicinal product are possible. The food supplements pathway will remain, but is likely to be least until 2011 old national increase also for various member states is less inhibited uncertainties administrative trail. The directive 2004/24/EC for THMP is put to test in all member states and the solution of practical issues specifically associated with the transfer from old to new registrations a challenge to all national regulatory bodies and the EMEA/HMPC. A market clarification and increased level can be expected, however manufacturer and product diversity may be diminished. 8 REFERENCES Barnes J. 2003. Quality, efficacy and safety of complementary medicines: Fashions, facts and the future. J. Clin. Pharmacol. Pharmacol. Res. Ernst Legislation relating to nutraceuticals in the European Union with a focus on botanical-sourced products. Toxicol. ; 221:75- 87. Elvin-Lewis M. 2005. Safety Associated with Herbal Ingredients. In Steve LT (Ed): Advances in Food and Nutrition Austrian Approach and Experience. Conference documentation: The New Regulatory Framework for Herbal Medicinal Products 2nd Annual Summit INFORMA, Vienna, Austria, 27-28 June. Vanherweghem JL. 2002. Renal interstitial fibrosis and urothelial carcinoma associated with the use of Herbal Medicinal Products in the European Union. Oral presentation at the 3rd ECA conference Quality aspects of Herbal Medicinal Products in Europe. Nov. Singh Potential for interaction of G, Seitz K, experience of operating the traditional herbal registration scheme in the UK. Conference documentation: The New Regulatory Framework for Herbal Medicinal Products 2nd Annual Summit, INFORMA, Vienna, Austria, 27-28 June. \u00a9 2007 Los Autores Derechos de Publicaci\u00f3n \u00a9 2007 Bolet\u00edn Latinoamericano y del Ca ribe de Plantas Medicinales y Arom\u00e1ticas, 6 (4), 112 - 117 BLACPMA ISSN 0717 7917 Especial Regulaci\u00f3n Tradit ional Use Directive on the Herbal Product Markets in the United Kingdom, Germany and Spain [El impacto de la Directiva Europea de Uso Tradicional en los mercados n acionales del Reino Unido, Alemania y Espa\u00f1a] Wieland PESCHEL Centre for Pharmacognosy and Phytotherapy, Sc hool iversity of 1AX London, United Kingdom *Contact: wieland.pesche l@pharmacy.ac.uk Recibido el 13 de Abril de 2007; Aceptado el 19 de Julio de 2007 Abstract Herbal products have been regulated in different European member states either as medicinal product, as medicinal product, food or medicinal product regulation has started also for manufacturers of herbal medicin e. the industry will vary between European member states according to the respective starting point. It is li kely to be larger in countries, where much of the industry has been operating in a rather unregulated market. In other countries, manufacturers a re better prepared, because they had high or pharmacovigilance procedures. This current in three Eu ropean member states with different hist ory of herbal medicinal product regulation. The examples of UK, Spain and Germany demonstrate th challenges of regulation and which may be relevant also Latin American countries in the future. Keywords: Traditional European Medicine, herbal medicine regulation, Spain, UK, Germany. Resumen Los productos herbales han sido regulados en Europa de manera diferente, ya sea como producto medicinal, como \"producto herbal tradicional\", como suplemento a limentario o incluso dejados en un ambiente desregulado. Con la nueva Directiva Europea (2004/24 /EC) para el registro simplificado de productos trad icionales ha empezado una nueva era de regul aci\u00f3n de productos medicinales para los productores de medicinas herbales. El impact o de esta regulaci\u00f3n en la indus tria variara entre los distinto s estados europeos de acuerdo a sus respectivos puntos de partida en lo que a regulaci\u00f3n na cional refiere. El impacto se r\u00e1 posiblemente mayor en pa\u00eds es donde la industria ha v enido operando en un mercado m\u00e1s o menos desregulado. En otros pa\u00edses, los productores estan mejor preparados ya que ven\u00edan largo tie mpo obligados a cumplir normas de calidad elevad as incluyendo GMPs, farmacovigilancia o ensa yos de estabilidad. Este art\u00edculo resum e la situaci\u00f3n actual de tres miembros de la Uni\u00f3n Europea con diferent es historias de procedimientos para la regulaci\u00f3n y armonizac i\u00f3n de los productos herbales. Los ejemplos de Espa\u00f1a, Reino Unido y Alem ania pueden ser relevantes para los pa\u00edses Latinoamericanos en el futuro. Palabras clave: Medicinas Tradicinales Europeas, regulaci\u00f3n de me dicamentos herbales, Espa\u00f1a, Reino Unido, Alemania. List of Abbreviations: AGEMED Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios (Spain) EC European Commission HMP Herbal Medicinal on UK, Germany and Spain Peschel Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 113 1 FROM AN UNREGULATED TO A REGULATED ENVIRONMENT - THE NEW CHALLENGE IN UK Before implementation of the European Traditional Use Directive 2004/24/EC herbal products (HP) reached the UK market usually by three different routes: (1) as a fully licensed medicine, (2) as from a full licence exempted herbal remedy (so called section 12( 2) exempts), or (3) as food supplement. (1) A marketing authorisation (MA) can be obtained under the Medicines for Human Regulations 1994 (SI 3144/1994) which largely transposed Directive 2001/83/EC law. Under Regulati ons most industrially produced MP that are placed on the market are required to be authorised demonstrating standards of quality, safety and efficacy. This pathway including simplified applications was of the Medicines 1968 (and regulation 1(3) of the 1994 Regulations) exempted herbal remedies that are not required are no specific requirements as to safety, quality or efficacy. No written claims are permitted and there is no specific requirement in terms of consumer information and safe usage. The original idea was to facilit ate HMP market access for herbal practitioners to make up herbal remedies without license on the premises from which they are supplied and to prescribe such for this pathway has converted over the years market access also for industrially produced remedies (tablets, as food supplement, which was uncomplicated \"if the safe food use can be demonstrated for a herb\". It also allowed health maintenance claims, treat, or prevent a clinical condition. This health maintenance claim must be substantiated, if requested by Trading Standard Officers or the Advertising Standards Authority. A typical by manufacturers. Some were defined by a lacking pharmacovigilance system, the categories (2) and (3) are the predestined trouble maker and responsible for major safety concerns. Colonial history and ongoing multiple immigration formed a market particularly vulnerable to \"non-regulation\". extensive international trade in unlicensed HP lead to various cases substitution, of 90,000 tablets containing a toxic ingredient, and in 2003 the MHRA found that a product containing 11.7% mercury by weight was available in 35 traditional Chinese medicine outlets. But not only risk to public health and public confidence, but also a risk to responsible bus inesses was stated by authorities: Manufacturers working under high quality standards have complained to the MHRA that they are undercut on price by those who formulate their products with low grade implemented the British authorities and provides a new fourth category, by now mostly as transitional protection for products on products have been newly licensed under this far. many of the old Section 12(2) products will automatically fall under the traditional use category and reap the benefit of the long transitional period until 30/04/2011. By then, all THMP requirements have to be fulfilled otherwise the product has to be withdrawn from the market. The extraordinary new requirements for the British food industry lead to a costs and benefit calculation by the tens pounds are the additional costs with registering a product under the Directive as compared with the cost for an unli censed herbal remedy on the largely unregulated market. This will vary according to the nature of the product and the circumstances of the individual company. Size may be relevant, for example, micro and small companies be insufficiently equipped to carry out certain activities in-house and may need to buy in help. On the other hand, a medium sized or larger company that wishes to enter a number of European markets may well decide it is worth having state of the art dossiers and quality controls in order to minimise the The Impact of the European Traditional Use Directive on UK, Germany and Spain Peschel Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 114 risk of delay arising from queries from the various regulatory authorities. If by 2011 around ed incurring various costs at an average of \u00a340,000 per registration, and if about 50% of the registrations related to UK companies, this would represent a cost to UK companies of about \u00a310m spread over 6 years for bringing these products into regulation. This does not include some additional expenditure, notably in premises or equipment improvement, that some companies have recognised were needed in the interests of good standards (Anderson, Barnes, 2003; Helliwell, 2007; Mills, 2006; Woodfield, 2007, MHRA website) 2 NEW BORDERLINES - THE DEVELOPMENT IN GERMANY Compared to the UK, the new European directive is of minor impact for regulators, customers and manufacturers in Germany because of four reasons: (1) HP with health claims have been traditionally treated as MP with similar quality and safety standards, (2) several monographs originating from the commission E of the Authority) (3) a comparable paragraph for traditional use remedies has been created with the 5th amendment of German drug law (5. AMG-Novelle, 1994) after a long cleaning process of the pharmaceutical market, and (4) HMP were produced by small and medium pharmaceutical enterprises, which were working under pharma-specific production/documentation standards including control/inspection by regional, federal and acceptance of traditi onal use as prove for quality and safety (point 3) is a transitional regulation only, caused by major delays in the all German on the market (\u00a7105 AMG together with \u00a7109a). Traditional MP, which were on the market before 1978, got a provisional MA until the post-marketing procedure has been completed. New products even if they were traditionally used. This refers not only to herbal MP, but also to any other \"traditional\" remedies. Because of its specific history Germany implemented as the first MS the Directive Table 1. General overview on types of applications and market size for HMP in Germany (BfArM according \u00a7\u00a7 21,22 AMG Requirements as for traditional, homeopathic or in \u00a7 109a AMG, valid for traditional MP which were on the market before 1978 (not for herbals only!), 1050 food or cosmetic law LMBG, \u00a7 5 of NemV No statistics available The Impact of the European Traditional Use Directive on UK, Germany and Spain Peschel Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 115 2004/24/EC into national law (\u00a7 39a - 39d AMG), which applies since September 2005. Now, traditional remedies have access to the market as \"new products\", if they are comparable to preparations which fulfil 30 years traditional use (15 years thereof in Europe). This European traditional and 39a AMG refer to herbal products only, but in future the extension to traditional remedies of animal, mineral or synthetic origin can be expected. As in other countries, Germany had already a levelled 3 class system (full MA, WEU, traditional MP) for herbals under medicine law. For historical and market size may have \"Standardzulassungen\" (s pecialities), which are standard market authorisations without need for a single case MA procedure of common/traditional product is obviously more than 30 years on the market and health claims may strengthen the market position. Last but not least exists a large variety of food supplements containing mixtures of vitamins, minerals etc. plus herbal under a less restrictive food law (LMBG). This means that only notification at the Federal Institute for Consumer Protection and regulatory burden of pharmaceutical law. Food supplements which contain the same ingredients in similar or lower concentrations of reach frequently uncontrolled products- support the work of authorities to observe the market. Manufacturers and wholesalers of food supplements are often challenged legally and have to justify the priority of food over medicine. Hence, the market control is partly performed by self-regulating forces with considerable impact competition between highly regulated expensive and low regulated supplement has been increased, since herbal medicine, apart from very few exemptions, are not any longer reimbursed by health insurances. Furthermore the high price sale via pharmacies is increasingly challenged by drugstores, supermarkets and the internet market. Nevertheless it will be likely interesting for manufacturers to access the market with \"European traditionals\" as an alternative to well-established-use bibliographic procedures. The justification of the traditional use in Europe will be in some cases easier than the reference to consolidated monographs or specifically WEU monograph standards. a -listed according to the national \u00a7109a- has been sold for more than 30 years, but increase of concentrations for the new concern for the small and medium phytopharmaceutical industry. Product history and existing data, potential and market strategy distribution strategy case by case (Roether, 2006; BfArM website). 3 PROBLEMATIC DEAL WITH OLD CATEGORIES - THE TRANSITION applications or, the traditional ones, with less quality, safety and efficacy standards. The first mentioned is in on UK, Germany and Spain Peschel Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 116 Basically, herbal products (defined in Article 42, paragraph 1 of the Spanish Medicines Law 25/1990) with a particular therapeutic/pharmaceutical activity are considered as MP as defined in Article 8.1. of 25/1990. Therefore manufacturing, distribution and sale of these products must follow the same pharmaceutical rules as any other MP. Pharmacological, toxicological and clinical studies may be in principle replaced by bibliographic documentation for non-prescription MP. These so called E.F.P. products (Especialidad Farmac\u00e9utica Publicitaria) according to the Ministerial order of 17/09/1982 are extract-based HP which are transferred now into the sale (freely but not ambulant) not restricted to pharmacies when no therapeutic claims are made, but without a clear definition or listing. This Law also distinguishes between Herbal Medicinal Products and \"Phytotraditional Medicinal Products\" in Title X article 117 (fees for again without giving definitions or listings. Preparations solely medicinal plants or parts of plants in a cut or powdered state must be included in the Special Register of Medicinal Plants of the AGEMED established in the Ministerial Order of 03/10/1973 and usually referred to as P.M. products (planta medicinal). to Exempted from this are those preparations that contain just one species and included in the Annex of the this Ministerial Order of 03/10/1973 (without indications): \"medicinal plants and their preparations (as single species) without an indication claim that are included in an Annex, do not need to register and no indication claim may be made.\" In this case, it is sufficient with an administrative notification following the terms of Decree annex of 110 plants has been officially updated only once in 1976. But it was possible to apply for the inclusion of medicinal plants or its parts. This has been happening without official publication throughout the years containing now around 170 species. In addition, with the order SCO/190/2004 a negative list amends the Annex with toxic plants whose sale is or risks With the Royal Decree of 16/11/1983 (Regulation on manufacturing and trade of 23 vegetal species of use in food) the registration of the most common herbal teas has been located under responsibility of the Ministry of Agriculture, i.e. outside medicine law. Unfortunately the majority of these 23 plants are also included in the described list of herbal species for medicinal use under AGEMED responsibility. There is no clear demarcation between foodstuff and medicine which should be determined in each case by the intention of use. Apart from that, food supplements were traditionally not defined in the Spanish law and could therefore not compete with (traditional) HP of other categories. First regulation started with the EU directives in the 90s. Whereas and P.M. products benefits herbal of non-listed species as food supplements in other MS, could however imported into Spain. Already imported supplements are frequently withdrawn from national has lead to complaints from importing food supplement companies and formal legal action. In March 2007 the European Commission has even decided, to take Spain to the European Court of Justice for its systematic barrier for the import plant based products from other MS as it is infringing the current rules of the free movement of goods in the internal market. The EC states that the Spanish restrictive interpretation of the relevant law goes beyond what is necessary in terms of public health. (European Commission, 2007) Summarising, it can be stated that the HP legislation in Spain -as historically developed- generated a series of categories in order to reflect the practical use and associated necessary quality/safety standards. However, due to partial overlapping of these categories and lacking modernisation of the law it is somewhat orphaned and will face a radical change by EU legislation. Although 2004/24/EC will offer a new host for Spanish traditional HP, a major issue for re-classification is that HP, which are considered as medicine, can be distributed only via The Impact of the European Traditional Use Directive on UK, Germany and Spain Peschel Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 117 pharmacies. In 2004 around 15 manufacturers produced around 300 HMP reaching the market via 20.000 pharmacies. In contrast around 200 small manufacturers of around 3800 herbolerias. Clear demarcation avoiding 250 species for free sale in 'herboristerias'. Considering the estimated HP annual turnover of 360 million Euro a political hot potato has to be touched by Spanish regulators which is further aggravated by pressure of food supplement manufacturers of other European MS claiming free access to the Spanish market (Casero, 2003; Ricq, 2004; AGEMED, 2007). 4 CONCLUSIONS The example and Spain demonstrate the diversity of regulatory situation for herbal medicine at the starting point of the European harmonisation process - in particular the grey area between foodstuffs and medicine and the borderline between well traditional community monograph/listing systems and other standards the national competent authorities to simplify and harmonise the herbal product market. New regulatory hurdles for herbal medicinal products are justified by the safety argument and the political (and commercial) goal of an unrestricted European market. The consumer/patient should benefit in regulations, increased major burden already now for the right strategy within the transition period. The introduction documents Ahead of moaning over additional requirements it should not be forgotten, that national HP will have easy market access across Europe, once they comply with European standards set a trial and error path will unfold issues and solutions on the way to the right balance between support for local industry, freedom of the market and consumer protection. The attentive observation - facilitated by a transparency of web based information of European and national organisations - may help regulators in Latin America and elsewhere taking decisions for their Furthermore any grower, manufacturer importer herbal starting materials who envisages the European market should be familiar with the currently changing situation. 5 REFERENCES Anderson L. Quality a UK regulatory perspective. Proceedings Traditional Herbal Medicine Symposium, London 2007. Barnes Quality, efficacy and safety of complementary medicines: Fashions, facts and the future. British J. Clin. Pharmacol. 55(3): 226-233. Bast A, Chandler R F, Choy P C, Delmulle L M, Gruenwald J, Halkes S B A, Keller K, Koeman J H, Peters P, Przyrembel H. 2002. Botanical health refers Spain to European court for ban on import of herbal products. Europa Press Room, Brussels, March 23. Helliwell K. 2007. Good manufacturing practice - Challenges for the herbal in dustry. Oral presentation at the Symposium Traditional Herbal Medicines. London, of Pharmacy, London, February. safety: resources: Symposium report: Pharmacovigilance of herbal medicines: Current st ate and future direction, London, 24-26 April 2006. Phytomedicine (In Press, Corrected Proof). Ricq O. Will the new legislation really the Spanish market? AENFP/AESGP Herbal committee presentation 2004. Roether B. 2006. How to Re gister Herbal Medicinal Products in the European Union. Oral presentation at the 3rd ECA conference Quality aspects of Herbal Medicinal Products in Europe. Nov. Vidal Casero C. 2003. El De sarrollo De La Legislacion Sobre Plantas Medicinales En La Comunidad Europea y su Incorporaci\u00f3n en el Ordenamiento Juridico Espa\u00f1ol. Su Problem\u00e1tica. Derecho y Salud 11: 85- 107. Woodfield R. 2007. MHRA's early experience of operating the traditional herbal registration scheme in the UK. Conference documentation: The New Regulatory Framework for Herbal Medicinal Products 2nd Annual Summit. INFORMA, Vienna, Austria, June. \u00a9 2007 Los Autores Derechos de Publicaci\u00f3n \u00a9 2007 Bolet\u00edn Latinoamericano y del Ca ribe de Plantas Medicinales y Arom\u00e1ticas, 6 (4), 118 - 124 BLACPMA ISSN 0717 7917 Especial Regulaci\u00f3n Issue on Regulation of Phytomedicines Antecedentes y situaci\u00f3n reguladora de la medicina herbaria en Cuba [Antecedents and current situation of the regulation of herbal medicines in Cuba] Maritza GONZ\u00c1LEZ RAM\u00cdREZ, Diadelis REMIREZ, Olga Lidia JACOBO Centro Estatal para el Control de la Calidad de los Medicame ntos (CECMED). Calle 200 No. 1706 e/ 17 y 19, Rpto. Siboney, Playa, Ciudad de La Habana. Cuba CP ; Apdo. Postal 16065 Telf. Recibido el 13 de Abril de 2007; Aceptado el 19 de Julio de 2007 Abstract Very few plant species have been studied fo r medical purposes and we have data about their safety a nd efficacy only for an even smaller number of them. Most countries don't have a legal framework for the control of herbal medicines, and they adopted different foc uses in the authorization and commercialization of gerbil medicines. Cuba ha s a long tradition of use of medi cinal plants since the Spanish colonisation and Traditional Medicine is both recognized and integrated in its National System of Health in the 1990. The State Centre for t he Quality Control of Drugs (CECMED) as Regulatory Authority of Drugs of C uba has the task of both and establishing the framework to assure the quality, the security and the efficacy of the herbal medicines by implementing the herbal medicines, regulatory affairs. Resumen Muy pocas especies de plantas se han est udiado con prop\u00f3sitos m\u00e9dicos y un n\u00famero menor de ellas tienen estudios realizados sob re su seguridad y eficacia. La mayor\u00eda de los pa\u00edses no cuentan con un marco legal para el control de los medicamentos herbarios, ado pt\u00e1ndose diversos enfoques en la autorizaci\u00f3n y comercializaci\u00f3n de los mi smos. Cuba tiene una tradici\u00f3n de uso de las plantas medicinal es desde la \u00e9poca de la colonia espa\u00f1ola y reconoce la Medicina Tradicional en su Sistema Nacional de Salud en el a\u00f1o 1990. El Centro Estatal para el Control de la Calidad de los Medicamentos (CECMED) como Autori dad Reguladora de Medicamentos de Cuba establece nuevas pol\u00edticas y el marco legal para asegurar la calidad, la seguridad y la efic acia de los medicamentos herbarios e identifica nuevas proyeccio nes referidas en este trabajo. Palabras clave: Cuba, medicamentos herbarios, regulaci\u00f3n. INTRODUCCION Durante las \u00faltimas d\u00e9cadas la utilizaci\u00f3n de las plantas medicinales y productos que se originan de ellas se han extendido en el mundo y han ganado una gran popularidad, sin embargo, muy pocas especies y productos se han estudiado con fines m\u00e9dicos y un n\u00famero menor cuenta con estudios realizados sobre su seguridad, eficacia y calidad (C\u00e1ceres, 1999). Tampoco existe un marco legal sobre las plantas medicinales y los medicamentos herbarios en la mayor\u00eda de los pa\u00edses, adopt\u00e1ndose diversos enfoques en la autorizaci\u00f3n y comercializaci\u00f3n de los mismos (OMS, 2002). Por los problemas anteriores y teniendo en cuenta la tradici\u00f3n hist\u00f3rica y popularidad sobre el uso de las plantas medicinales y medicamentos herbarios, el Centro Estatal para el Control de la Calidad de los Medicamentos (CECMED) como Autoridad Reguladora de Medicamentos de Cuba ha establecido nuevas pol\u00edticas y el marco legal para asegurar la calidad, la seguridad y la eficacia de los mismos para proteger la salud de los consumidores. El presente trabajo tiene como objetivo mostrar algunos antecedentes en Cuba sobre el uso de las plantas medicinales y el trabajo realizado en el marco legal para el registro y control de los medicamentos herbarios, as\u00ed como algunas proyecciones de trabajo. Regulaci\u00f3n de medicamentos herbales en Cuba Gonz\u00e1lez Ram\u00edrez et al. Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 119 DESARROLLO Antecedentes en Cuba. En Cuba, la introducci\u00f3n de la Medicina Tradicional comienza en el siglo XV, primero por la colonia espa\u00f1ola y m\u00e1s tarde por africanos, chinos y yucatecas. No es hasta mediados del siglo XX que alcanza su m\u00e1xima expresi\u00f3n con el Doctor Juan Tom\u00e1s Roig, quien identifica 595 especies que eran empleadas por la poblaci\u00f3n cubana para diferentes usos curativos (Roig, 1945) y hace un llamado a la comunidad cient\u00edfica nacional para que se estudien dichas plantas con el objetivo de comprobar su seguridad y eficacia, planteando adem\u00e1s la necesidad de desarrollar la industria farmac\u00e9utica nacional. En los a\u00f1os 60 la investigaci\u00f3n cient\u00edfica sobre las plantas medicinales comienza a desarrollarse en el pa\u00eds de manera ascendente, aunque de forma aislada por distintos investigadores y m\u00e1s bien con fines acad\u00e9micos. En los a\u00f1os 70 se inaugura la Estaci\u00f3n Experimental de Plantas Medicinales \"Juan Tom\u00e1s Roig\" con el objetivo de realizar estudios completos con las plantas medicinales de Cuba, pero no fue hasta la d\u00e9cada de los 90 que se establece un Programa Nacional para el Desarrollo y la Generalizaci\u00f3n de la Medicina Tradicional y Na tural con participaci\u00f3n de todas las unidades e instituciones de Atenci\u00f3n M\u00e9dica del Sistema Nacional de Salud y otras instituciones de investigaci\u00f3n y desarrollo. Posteriormente se crea el Centro Nacional de Medicina Tradicional y Natural quien tiene como funci\u00f3n establecer las bases metodol\u00f3gicas necesarias para desarrollar, controlar y evaluar la aplicaci\u00f3n del Programa. En el a\u00f1o 1989 se crea oficialmente por el Ministerio de Salud P\u00fablica el CECMED como Autoridad Reguladora de Medicamentos de Cuba, encargado de promover y proteger la salud p\u00fablica a trav\u00e9s de un sistema regulador capaz de garantizar el acceso al mercado de los medicamentos con calidad, seguridad, eficacia e informaci\u00f3n veraz para su uso racional. En 1996 fue instituido el Bur\u00f3 Regulatorio para la Protecci\u00f3n de la Salud P\u00fablica como m\u00e1xima autoridad estatal para actuar en defensa de la salud, al que se subordina el CECMED y otras entidades para conformar el \u00d3rgano Regul ador Nacional para la Protecci\u00f3n de la Salud. En el a\u00f1o 2002 se crea el acuerdo No. 4282 del Comit\u00e9 Ejecutivo del Consejo de Ministro que establece las disposiciones para la consolidaci\u00f3n en el pa\u00eds de las estrategias de la Medicina Tradicional. Situaci\u00f3n reguladora sobre medicamentos herbarios en Cuba. El Ministerio de Salud P\u00fablica ha elaborado una serie de Normas Ramales sobre especificaciones generales de las drogas vegetales y sobre m\u00e9todos de ensayo y procesos tecnol\u00f3gicos de extractos fluidos y tinturas con el objetivo de guiar y orientar el trabajo de elaboraci\u00f3n y estandarizaci\u00f3n de los medicamentos herbarios. Se publica en el a\u00f1o 1992 una Gu\u00eda Terap\u00e9utica de Fitof\u00e1rmacos y Apif\u00e1rmacos sobre la base de algunas investigaciones realizadas en Cuba con plantas medicinales cubanas y sobre reportes de la literatura cient\u00edfica y monograf\u00edas farmacop\u00e9icas internacionales. En la misma se incluyen un total de 233 formulaciones de fitof\u00e1rmacos para uso en diferentes indicaciones terap\u00e9uticas (Tabla 1) En el a\u00f1o 2000, el CECMED identifica la necesidad de incorporar a los productos naturales dentro de la pol\u00edtica de medicamentos, en el proceso normal de registro, control, producci\u00f3n y comercializaci\u00f3n, y traza estrategias para tratar los temas relacionados con la pol\u00edtica, la seguridad, la eficacia, la calidad, el acceso y el uso racional de los medicamentos herbarios, seg\u00fan las recomendaciones de la OMS. En un principio, la implementaci\u00f3n de las estrategias se ha basado f undamentalmente en los dos primeros objetivos, a partir de los cuales, se proporcionar\u00e1n las bases neces arias para conseguir los objetivos de acceso y uso racional. Uno de los aspectos m\u00e1s im portantes para asegurar la calidad, la seguridad y la eficacia de los medicamentos herbarios lo constituye el registro y control de los mismos. En el a\u00f1o 2002 se establecen por el CECMED los Requisitos para el registro de los medicamentos herbarios (CECMED, 2002) y como parte de la regulaci\u00f3n 16/2006 \"Directrices sobre Buenas Pr\u00e1cticas de Fabricaci\u00f3n de Producto Farmac\u00e9utico\", el anexo No. 3 de Buenas Pr\u00e1cticas de Medicamentos Herbarios. El Registro de Medicamentos de Origen Natural de uso humano en la Rep\u00fablica de Cuba, tiene una vigencia de 5 a\u00f1os, al igual que la Renovaci\u00f3n que podr\u00e1 ser solicitada por per\u00edodos iguales y sucesivos 90 d\u00edas antes del vencimiento del Registro. En caso de modificaciones, el Titular del Registro o fabricante del producto tiene la obligaci\u00f3n de solicitar la aprobaci\u00f3n de las modificaciones dentro del per\u00edodo de vigencia del Registro del medicamento. Regulaci\u00f3n de medicamentos herbales en Cuba Gonz\u00e1lez Ram\u00edrez et al. Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 120 La estructura de los requisitos para el registro de los medicamentos herbarios es la siguiente: a) Informaciones generales: Incluye informaci\u00f3n general sobre las solicitudes de tr\u00e1mites, los productos que ser\u00e1n o no objeto de inscripci\u00f3n y las categor\u00edas (A, B y C) establecidas para estos productos. Cuadro 1: Categor\u00edas de los medicamentos de origen natural en la legislaci\u00f3n cubana. A Medicamentos Herbarios Nuevos y Medicamentos Herbarios Tradicionales con una nueva v\u00eda de administraci\u00f3n y/o indicaci\u00f3n , respaldados por estudios farmacol\u00f3gicos, toxicol\u00f3gicos y cl\u00ednicos controlados. B Medicamentos Herbarios Tradicionales respaldados por estudios farmacol\u00f3gicos y toxicol\u00f3gicos y por algunos estudios cl\u00ednicos realizados (estudios de cohorte, estudios de utilizaci\u00f3n, caso control, series de casos y publicaciones indexadas). C Medicamentos Herbarios Tradicionales respaldados por informaci\u00f3n etnom\u00e9dica y etnoalimentaria del lugar de procedencia del material vegetal, por documentaci\u00f3n tecnocient\u00edfica y por estudios de toxicidad aguda. b) T\u00e9rminos y Definiciones: Incluye los t\u00e9rminos y definiciones adoptados por el CECMED en este campo, que permiten una mejor comprensi\u00f3n del tema. c) Documentaci\u00f3n de solicitudes de tr\u00e1mites: Este cap\u00edtulo incluye las cuatro partes que forman la documentaci\u00f3n del expediente del medicamento, relacionadas a continuaci\u00f3n: PARTE 1. Informaci\u00f3n administrativa. Incluye los datos generales del solicitante y fabricante, una informaci\u00f3n general del producto terminado, as\u00ed como las muestras a incluir del producto terminado, sustancias de referencia, material de envase y material informativo del producto que se desee promocionar. PARTE II. Informaci\u00f3n Qu\u00edmico-Farmac\u00e9utica y Biol\u00f3gica. Se presentan todos los aspectos relacionados con la calidad del producto. PARTE III. Informaci\u00f3n Precl\u00ednica. Incluye los aspectos relacionados con la toxicidad del producto y las propiedades farmacol\u00f3gicas comprobadas. PARTE IV. Informaci\u00f3n Cl\u00ednica. Incluye los aspectos relacionados con los estudios cl\u00ednicos, para demostrar la eficacia, incluyendo los datos cl\u00ednicos y biol\u00f3gicos m\u00e1s significativos para el establecimiento de la seguridad, para la indicaci\u00f3n propuesta y si la dosificaci\u00f3n prevista es la adecuada . d) Anexos: Incluye los modelos e informaci\u00f3n que se anexa como parte del contenido de la regulaci\u00f3n. e) Bibliograf\u00eda: Se relacionan las referencias bibliogr\u00e1ficas consultadas sobre esta materia. Las fuentes primarias sobre las que se han desarrollado estos requisitos para el registro y control, han sido las directivas de la OMS y las legislaciones de 15 pa\u00edses de Iberoam\u00e9rica sobre productos naturales (WHO, 1998, 2001, 2004a, 2004b, 2005; OMS, 1993, 2003; Garc\u00eda y C\u00e1ceres, 2000; Fuentes et al, 2000). Las instituciones implicadas con el cumplimiento de la Regulaci\u00f3n que estable los requisitos para el registro y control de los medicamentos herbarios, se presentan en la figura 1. El resultado de la implementaci\u00f3n y generalizaci\u00f3n de la Regulaci\u00f3n ha tenido un gran impacto para el trabajo de la Autoridad Reguladora en funci\u00f3n del control y regulaci\u00f3n de los medicamentos que se comercializan en el pa\u00eds, al disponer por primera vez de una regulaci\u00f3n nacional donde se establecen los Requisitos para el registro y control de los medicamentos herbarios de uso humano y ha permitido adem\u00e1s servir de gu\u00eda a las instituciones de investigaci\u00f3n y desarrollo, la industria, las farmacias y almacenes en el desarrollo, la evaluaci\u00f3n y el control de tales productos. En las unidades de Atenci\u00f3n Primaria y Secundaria de Sa lud, tambi\u00e9n ha jugado un papel importante la implementaci\u00f3n de esta regulaci\u00f3n, donde cada vez el acceso a estos medicamentos es mayor y la realizaci\u00f3n de estudios cl\u00ednicos que corroboren la eficacia de los mismos va permitiendo su uso racional al mismo tiempo. Regulaci\u00f3n de medicamentos herbales en Cuba Gonz\u00e1lez Ram\u00edrez et al. Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 121 Tabla 1. Relaci\u00f3n de algunos medicamentos herbarios m\u00e1s utilizados, incluidos en la Gu\u00eda Terap\u00e9utic a de Fitof\u00e1rmacos y Apif\u00e1rmacos del Ministerio de Salud P\u00fablic a de la Rep\u00fablica de Cuba. Medicamento herbario Especie bot\u00e1nica incluida en su composici\u00f3n Indicaci\u00f3n Terap\u00e9utica/s Crema de Cebolla Allium cepae L. Cicatrizante y Extracto Fluido Cal\u00e9ndula 10 y 20 % Cassia grandis L. Antian\u00e9mico, antif\u00fangico Tintura Lim\u00f3n Citrus aurantifolia C. Antiespasm\u00f3dico Tintura de Naranja Agria 20 % Citrus aurantium L. Flebot\u00f3nico, diur\u00e9tico Jarabe de Naranja dulce Citrus sinensis L. Diur\u00e9tico, flebot\u00f3nico Jarabe de Ca\u00f1a santa Crema de Ca\u00f1a santa 5 % Cymbopogon citratus D.C. Diur\u00e9tica, antihipertensivo, antiinflamatorio. Extracto Flu\u00eddo de Tilo Jarabe de Tilo 20 % Justicia pectoralis J. Sedante Extracto alcoh\u00f3lico de Quitadolor Lippia alba M. Analg\u00e9sico Tintura de Manzanilla 20 % Mentha arvensis L. Antiespasm\u00f3dico, antiiflamtorio de v\u00edas respiratorias de menta Mentha piperita L. Antiespasm\u00f3dico L. Antiespasm\u00f3dico Tintura de Albahaca blanca Albahaca blanca Ocimum basilicum L. Antiespasm\u00f3dico Extracto Flu\u00eddo de Te de ri\u00f1\u00f3n Jarabe de Te de ri\u00f1\u00f3n 20 % Orthosiphon aristatus B. Diur\u00e9tico Extracto Flu\u00eddo Expectorante, antitusivo Tintura de guayaba % de Guayaba Psidium guajaba L. Antif\u00fangico, Jarabe de Romero Rosmarinus officinalis L. Antis\u00e9ptico Salvia de castilla Salvia officinalis L. Broncodilatador, expectorante Tintura de Guacamaya francesa 20 % Senna alata R. Antif\u00fangica Jarabe de Ma\u00edz Zea mays L. Diur\u00e9tico Extracto de Jengibre Tintura de Jengibre , diarreas. Regulaci\u00f3n de herbales en Cuba Gonz\u00e1lez Ram\u00edrez et al. Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 122 Tabla 2. Tiempos (en d\u00edas naturales) establecidos para cada tipo de solicitudes de tr\u00e1mites de registro. Solicitud Tipo Inicial Completamiento de la Documentaci\u00f3n Total CECMED Solicitante CECMED Inscripci\u00f3n A 180 90 105 375 Inscripci\u00f3n B y C 150 90 105 345 Renovaci\u00f3n 120 90 105 315 Modificaci\u00f3n 120 90 105 315 Tabla 3. Plantas Medicinales que ser\u00e1n incl uidas en futuras ediciones de la Farmacopea Cubana de Plantas Medicinales del Ministerio de Salud P\u00fablica de la Republica de Cuba. Especie/s bot\u00e1nica/s Nombre com\u00fan Cate gor\u00eda(s) Terap\u00e9utica/s aurantium Naranja agria Flebot\u00f3nico, diur\u00e9tico Citrus nobilis L. Mandarina dismenorrea, antioxidante L. Sag\u00fa Diarr\u00e9ico, emoliente, enfermedades de la L. herbales en Cuba Gonz\u00e1lez Ram\u00edrez et al. Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 123 Tabla 3 (Continuaci\u00f3n). Plantas Medicinales que ser\u00e1n incluidas en futuras edicio nes de la Farmacopea Cubana de Plantas Medicinales del Ministerio de Salud P\u00fablic a de la Republica de Cuba. Especie/s bot\u00e1nica/s Nombre com\u00fan Cate Romero Antis\u00e9ptico Ruta graveolens Sedante Salvia officinalis L. Salvia de castilla Broncodilatador, expectorante Senna alata Vahl Verbena Antiparasitario, afecciones renales y de la piel, antimicrobiano. Tamarindus indica L. Tamarindo Antiinflamatorio Thymus vulgaris L. Tomillo Afecciones respiratorias agudas y cr\u00f3nicas Xanthium occidentalis Guisazo de caballo Diur\u00e9tico Zea mays L. Ma\u00edz Diur\u00e9tico Zingiber officinale R. Jengibre Problemas digestivos, tonificante Hasta la fecha el CECMED ha registrado un total de 60 medicamentos herbarios nacionales y de importaci\u00f3n que se producen en la industria. Los medicamentos que se elaboran de manera semi-industrial, que son la mayor\u00eda de los que se producen en el pa\u00eds en los centros de producci\u00f3n local y dispensarios farmac\u00e9uticos, con condiciones tecnol\u00f3gicas y recursos materiales m\u00ednimos, relacionados en la tabla 1 , siguen otros requisitos establecidos en la Regulaci\u00f3n 29/2000 \"Requisitos para las solicitudes de autorizaci\u00f3n de uso de medicamentos de origen natural de uso humano, de producciones locales y dispensariales\", para su autorizaci\u00f3n que est\u00e1n espec\u00edficamente relacionados con la calidad del prod ucto y que responden a productos que se elaboran a partir de un listado de plantas autorizadas para el cu al se tuvo en cuenta la tradici\u00f3n de uso en Cuba con fines medicinales y las investigaciones realizadas en el pa\u00eds y otros reportes de la literatura cient\u00edfica sobre seguridad y eficacia. Los tiempos establecidos en el reglamento de registro para las solicitudes de tr\u00e1mites de inscripci\u00f3n, renovaci\u00f3n y modificaci\u00f3n en el registro, se presentan en la tabla 2. Proyecciones de trabajo El CECMED ha establecido proyecciones de trabajo con el objetivo de perfeccionar la base legal para la regulaci\u00f3n de medicamentos herbarios con la elaboraci\u00f3n y actualizaci\u00f3n de pautas, directrices t\u00e9cnicas y metodolog\u00edas nacionales para evaluar la seguridad, la eficacia y la calidad de las plantas medicinales y medicamentos herbarios, entre las que se pueden mencionar, gu\u00edas sobre m\u00e9todos de ensayos para el control de la calidad, gu\u00eda sobre especificaciones de calidad y criterios de aceptaci\u00f3n Regulaci\u00f3n de medicamentos herbales en Cuba Gonz\u00e1lez Ram\u00edrez et al. Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 124 de las drogas vegetales y productos terminados y metodolog\u00edas para la investigaci\u00f3n de las plantas medicinales. Estos documentos ser\u00e1n elaborados teniendo en cuenta las directrices de la OMS y nuestras condiciones de trabajo. Tambi\u00e9n est\u00e1 en ejecuci\u00f3n el proyecto de elaboraci\u00f3n de las monograf\u00edas de las plantas cubanas que formar\u00e1n parte de la primera edici \u00f3n de la Farmacopea Cubana de Plantas Medicinales con las especies relacionadas en la tabla 3 , as\u00ed como la elaboraci\u00f3n de las buenas pr\u00e1cticas agr\u00edcolas, de recolecci\u00f3n y de conservaci\u00f3n de las plantas medicinales. Otra de las proyecciones est\u00e1 relacionada con el desarrollo de las pautas para el consumidor sobre la informaci\u00f3n necesaria para el uso correcto de las plantas medicinales. CONCLUSIONES Cuba integra la Medicina Tradicional en el Sistema Nacional de Salud y crea en el a\u00f1o 1995 un Programa Nacional para el Desarrollo y Generalizaci\u00f3n de la Medicina Tradicional. El CECMED como Autoridad Nacional Reguladora de Medicamentos, en el a\u00f1o 2000, traza algunas estrategias de trabajo para asegurar la calidad, la seguridad y la eficacia de las plantas medicinales y medicamentos herbarios. Se implementa y perfecc iona el marco legal para el registro y control de los medicamentos herbarios a partir del a\u00f1o 2002. Se trazan proyectos de elaboraci\u00f3n de documentos regulatorios relacionados con las buenas pr\u00e1cticas agr\u00edcolas, de recolecci\u00f3n y conservaci\u00f3n de las plantas medicinales, sobre la calidad, la seguridad y la eficacia de los medicamentos herbarios y sobre las pautas para el consumidor sobre la informaci\u00f3n necesaria para el uso correcto de las plantas medicinales. BIBLIOGRAF\u00cdA CECMED. 2002. Requisitos para las solicitudes de tr\u00e1mites de inscripci\u00f3n, renovaci\u00f3n y modificaci\u00f3n de los medicamentos de origen natural de uso humano. CECMED Regulaci\u00f3n No. 28-2002, La Habana, Cuba. C\u00e1ceres A. 1999. Plantas de uso medicinal en Guatemala, Editorial Universitaria, Ciudad de Guatemala, Guatemala. Fuentes Fiallo VR, Lemes Hern\u00e1ndez CM, Rodr\u00edguez Ferrad\u00e1 CA, Germos\u00e9n-Robineau L. 2000. Manual de cultivo y conservaci\u00f3n de plantas medicinales , Tomo II, Cuba . Editora Centenario, S.A., Santo Domingo, Rep\u00fablica Dominicana. Garc\u00eda M, C\u00e1ceres A. 2000. Legislaci\u00f3n en Iberoam\u00e9rica sobre Fitof\u00e1rmacos y Productos Naturales . Ed. CYTED-LEBi-ASACIMSS-EU, Costa Rica. Roig Mesa JT. 1945. Plantas medicinales, arom\u00e1ticas o venenosas de Cuba, Editorial Cient\u00edfico-T\u00e9cnica, La Habana, Cuba. OMS, UICN, WWF. 1993. Directrices sobre conservaci\u00f3n de plantas medicinales. UICN, Gland, Suiza. OMS. 2002. Estrategias de la OMS sobre la Medicina Tradicional 2002-2005 . WHO/EDM/TRM/2002.1, Ginebra, Suiza, OMS. 2003. Directrices de la OMS sobre buenas pr\u00e1cticas agr\u00edcolas y de recolecci\u00f3n (BPAR) de plantas medicinales. Ediciones de la OMS, Ginebra, Suiza. WHO. 1998. Quality Control Me thods for Medicinal Plants Materials. Editions of the OMS, Geneva, Switzerland. WHO. 2001. Legal Status of Traditional Medicine and Complementary/Alternative Medicine: A Worldwide Review. WHO/EDM/TRM/2001.2. Editions of the OMS, Geneva, Switzerland. WHO. 2004a. WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems, Editions of the OMS, Geneva, Switzerland. WHO. 2004b. WHO Guidelines on Developing Consumer Information on Use of Traditional, Complementary and Alternat ive Medicine. Editions of the OMS, Geneva, Switzerland. WHO. 2005. National Policy on Traditional Medicine and Regulation of Herbal Medicine. Report of WHO Global Survey. Editions of the OMS, Geneva, Switzerland. \u00a9 2007 Los Autores Derechos de Publicaci\u00f3n \u00a9 2007 Bolet\u00edn Latinoamericano y del Ca ribe de Plantas Medicinales y Arom\u00e1ticas, 6 (4), 125 - 128 BLACPMA ISSN 0717 7917 Especial Regulaci\u00f3n its way towards full regulation of herbal medicines related products, increasing imports of unregulated herbal products into the Island crea ting a need for protecting both our citizen s and local producers alike. From a practical legal point of view the current legal framework was based mainly in the Food and Drug Act 196 4, and the Food and Drug Regulations 1975, established by the Ministry of Health, but they did not refer to herbals and herbal medicines i n its contents. From 1999, Jamaican governmental and private institutions are working on the amendment of these acts and rticipating actively in international workshops to regulate phytomed icines both within the country and the Ca ribbean/Centro American region. However th e law will force growers to perform adequate laboratory tests that are often out of their economical reach, and the help of the admin istration has proposed to solve this developments the swer to \"what is the status on the Amendment?\" is still in limbo. Keywords: Jamaica, herbal medicines, regulatory affairs. Resumen Jamaica esta haciendo progresos hacia la re gulaci\u00f3n completa de los medicamentos herbar ios y productos relacionados como los su plementos alimentarios. Esto ha sido impulsado por el aumento de importaciones de productos herbarios no regulados en la isla, lo que cre o una necesidad de proteger tanto al consumidor como al productor local. Desde un punto de vista practico el marco legal basado en la Ley de Alimentos y Medicamentos de 1964 y las Regulac iones de Alimentos y Medicamentos de 1975, establecidas por el Ministerio de Salu d, pero estas no hac\u00edan menci\u00f3n de los productos herb arios. Desde 1999, el gobierno jamaicano e in stituciones privadas trabajan en la actualizaci\u00f3n de estas leyes por enmienda, adem\u00e1s de part icipar activamente en grupos de trabajos in ternacionales para regular tanto la situaci\u00f3n interna como la regional (Caribe/Centroam\u00e9rica). Sin embargo la regulaci\u00f3n del mercado herbario forzar a a los productores locales a realizar an\u00e1lisis que est\u00e1n fuera de su capacidad econ\u00f3mica, y la ayuda estatal ha sido propuesta como soluci\u00f3n. A pesar de todos estos avances l a respuesta a la situaci\u00f3n de la enmienda se encuentra aun en el limbo. Palabras clave: Jamaica, medicamentos herbarios, regulaci\u00f3n. INTRODUCTION Herbs are always difficult to characterise because of their complexity of active ingredients or compounds that are usually not known. History has shown that multiple choices exist for protecting human health. Since 1994 the natural products as preventative and remedies and herbals have drawn the attention of the Ministry of Health in Jamaica . The Ministry has a responsibility to protect the health of citizens, and therefore has to set laws to govern the registration, importation, manufacture, storage, distribution, sale and use of herbal medicinal products. The Food and Drug Act 1964, and the Food and Drug Regulations 1975, established by the Ministry of Health did not refer to herbals and herbal medicines in its contents. Regulation of herbal medicines in Jamaica Robertson Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 126 DEFINITIONS BY LEGISLATION SECTION 2- JAMAICA FDA Food- for food or drink by man, including chewing gum and any ingredient that may be mixed with food or drink for any purpose.\" disease, disorder, packaged stored for sale Q is an asset. The primary reason why standardization exists for herbal extracts is to achieve as much control in clinical double blind studies as It is to the claims on the labels. Safety contributes to improve the quality of life. Safety is the fundamental principle and the critical component of quality management. There is the common misconception that all natural products or plants are safe! Safety interactions. Today good agricultural practices (GAP) are now in place so as to avoid growing where the soil is contaminated with heavy metals, as well as collection of the wrong species and adulteration with other herbs. THE CURRENT STATE OF THE INDUSTRY In 1994, the Ministry of Health (MOH) saw the necessity to intervene in the escalating importation of herbal materials dietary supplements by treating these as \"drugs\". The Wholistic which founded by this author among other stakeholders and consumers in the industry, took the M.O.H to task to prove if an \"herb\" is a drug or a \"food\". The Association engaged the Ministry into a legal tangle along with media \"war\" with the medical practitioners during 1995-1999 . The former Chairman Dr. Robertson and the former President Dr. Vance Lannaman NMD, along with the stakeholders in the industry lobbied with the M.O.H before the Houses of Parliament. On March 22nd 1999, the Honourable Houses of Parliament a decision th at a special committee of the Association and \"The Joint Select Committee on Human Resources and Social Development\" (appointed by the Houses of Parliament and the Ministry of Health) met for one year preparing documentation to be submitted to Parliament to amend the FDA 1974 to include the following: 1. Herbal Remedies 2. Health Foods 3. Herbs 4. Finished Herbal Products 5. Herbal Materials 6. Dietary 7. OTC herbal products. Permanent Secretary in the M.O.H for perusal and submission to the Chief Parliamentary Council. In 2000 the Ministry of Health appointing a representative of each complementary medicinal therapy, formed an Advisory Panel for Complementary Medicine. Dr. Sonia Davidson MD. was appointed by the M.O.H as the Chairman. On November 13-16 2000 the Ministry of health hosted a Regional Meeting on Herbal Medicine, which was held in Jamaica. Participants from Barbados, Brazil, Canada, Chile, Guatemala, Jamaica, Mexico, Panama, USA and representatives from PAHO /and World Health Organisation all attended. This was an opportunity for drug regulators of various countries to come together to discuss the different issues surrounding the production, registration and use of herbal products and to develop a proposal on harmonized standards and regulations to assure safe safety and other as reference and guide for the discussion (Pan American Health Organization, 2002.). The Advisory Panel completed a document on procedures to harmonise with Complementary Alternative Medicine, which included the operations of herbal practitioners and therapists to be regulated. To date the amendments for Phytomedicines and the Practitioners of Complementary Medicine have not been included in the FDA amendments, or submitted for approval by the Honourable Houses of Parliament. Regulation of herbal medicines in Jamaica Robertson Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 127 PRESENT REGULATORY FRAMEWORK After a period of four years the changes of the Regulatory framework have been completed, and submitted to the Chief Parliamentary Council for adjustments since late 2006, but still no amendments are in place. The Ministry of Health has made reference taken by competent authorities in Australia, Canada, Germany, England and the United States, references to WHO guidelines on the assessment of herbal products and definitions were also adapted for use (WHO. 1998, 2001, 2004a., 2004b). There is not a Jamaican Pharmacopoeia in place. The British Pharmacopoeia (British Pharmacopoeial Commission, 2008) is instead required to be in all Pharmacies in the island . In addition, References can be made from \"The Complete German Commission E Monographs\" (Blumenthal et al., 1999) published by the American Botanical Council which also includes some Canadian herbal references. The Pharmacy Council in Jamaica has also made requests for their Laws to be amended to make it possible for herbals to be sold \"special shops\" which would be regulated by the Pharmacy Council. This too has not yet been amended. Since 2005 the Director of Standards and Regulation MOH and their officials along with representatives Practitioners met formerly a has down tremendously. Documentation Requirements for Registration of Herbal Remedies It is interesting that the application form from the Pharmaceutical and Regulatory Affairs unit is still under the Registration of Herbal products, food and drugs Act of 1964. This form has to answer pertinent questions such as a statement form must be: A\"Certificate of Free Sale \" that must be endorsed by the Jamaican Consulate in the country of origin. A \"Certificate of Analysis \" indicating tests for quality and potency. Five samples indicating Ceanothus spp. herb Piper Requirements for Health food must comply with a simplified procedure to be registered in Jamaica: Evaluation and review ingredients and concentration. Verification of label claims, purity of products Proof of approval in country of origin. Scientific support be are claims. Products, which exist and function principally as injectable presentations are not allowed and they can only be registered as prescription drugs. Secondly, there is a list restricted a list of restricted plant species). OUR CHALLENGES The need for an adequate laboratory support for testing our raw materials to acquire a Certificate of Analysis is most challenging for growers of raw materials. At present our Scientific Research Council is planning assistance in this area. This would assist the to provide requisite documentation for product approval. Regulation of herbal medicines in Jamaica Robertson Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 128 The questions asked daily by stakeholders is \"what is the status on the Amendment?\" Its answer is still in limbo. REFERENCES Blumenthal M, CW, Rister RRS, Klein S,. 1999. The Complete German Commission E Monographs: Therapeutic Guide to Herbal Botanical Council (Corporate Austin, TX. British Pharmacopoeia Commission. 2008. The British Pharmacopoeia. The Stationery Office, London UK. Director of Standards and Regulation. 2003. \"Regulations of Herbal November. Handa Aromatic Plants\"; Presentation in collaboration with ICS-UNIDO and CHBA. II Port of Spain, Trinidad. Amendments Submitted MOH No.PS/S11, 8.Aug.2003; Apr. 22 .2003. WHO. 1998. Quality Control Me thods for Medicinal Plants Materials. Editions of the OMS, Geneva, Switzerland. WHO. 2001. Legal Status of Traditional Medicine and Complementary/Alternative Medicine: A Worldwide Review. WHO/EDM/TRM/2001.2. Editions of the OMS, Geneva, Switzerland. WHO. 2004a. WHO Guidelines on Safety Monitoring of Herbal Medicines in Pharmacovigilance Systems, Editions of the OMS, Geneva, Switzerland. WHO. 2004b. WHO Guidelines on Developing Consumer Information on Use of Traditional, Complementary and Alternat ive Medicine. Editions of the OMS, Geneva, Switzerland. WHO. 2005. National Policy on Traditional Medicine and Regulation of Herbal Medicine. Report of WHO Global Survey. Editions of the OMS, Geneva, Switzerland. Jamaican Ministry of Health. 1964. Food and Drug Act. Kingston, Jamaica. Jamaican Ministry of Health. 1975. Food and Drug Regulations. Kingston, Jamaica. Pan American Health Organization. 2002. Traditional, Complementary and Alternative Medicines and Therapies: Evaluation Plan of Work 2000-2001 and Plan of Work 2002-2003. Washington, D.C. US. URL http://www.paho.org/English/HSP/HSO/HSO07/TRM ENG.pdf [Last accessed 18/10/07]. \u00a9 2007 Los Autores Derechos de Publicaci\u00f3n \u00a9 2007 Bolet\u00edn Latinoamericano y del Ca ribe de Plantas Medicinales y Arom\u00e1ticas, 6 (4), 129 - 136 BLACPMA ISSN 0717 7917 Especial Regulaci\u00f3n on Regulation of Phytomedicines An Overview on the Development in Re gulation and Control of Medicinal and Aromatic Plants in the Indian System of Medicine [Una panor\u00e1mica del desarrollo de la regulaci\u00f3n y control de plantas medicinales y arom\u00e1ticas en el sistema indio de medicina] Pulok K. MUKHERJEE*, M. VENKATESH, V. KUMAR School of Product Studies, ent hnology, well-recorded and well practiced knowledge of traditional herbal medicine s under indigenous system s of medicine like Ayurveda, Siddha and Unani. On the other hand, with about 6000 plants repr esenting about 75% of the medicinal needs of the third world co untries India is a major worldwide exporter of raw medicinal and aromatic plants and improve the herbal drug standards and promote Indian system of medicine. Government of India has been st iffening the herbal drug regulations from time to time by establishing various bodies to control the manufacture and sales drug. I t rds for natural products. A recent major m ove has been the convertion of The Department of Indian Systems of Me dicines and Homoeopathy (ISM & H) established in 1995 into the Department of Ayurveda, Yoga & Naturopathy, Unani, Siddha a nd Homoeopathy (AYUSH) in 2003. and whic h address the thrust areas ide ntified by the Department like up gradation of educational standards, quality control and standardizat ion of drugs, improving the avail ability of raw material, research and development and awar eness generation about the efficacy of the systems domestically and internationally. Keywords: India, herbal medicines, regulatory a ffairs, Ayurveda, Yoga, Naturopathy, Unani, Siddha. Resumen India tiene un uso de medicinas herbarias tr adicionales bien documentado y bien establ ecido bajo diversos sistemas ind\u00edgenas como el Ayurveda, Siddha y Unani. Por otro lado, con mas de 6000 especies de plantas representado el 75% de las necesida des medicinales de pa\u00edses del tercer mundo, India es un exportador mundial de drogas vege tales y especias. El gobierno hind\u00fa ha tomado varias iniciativas para mejorar y endurecer las normas de calidad en el sect or y establecer varios organismos de cont rol de su producci\u00f3n y venta. Tambi\u00e9n esta continuamente tomando medidas correctivas medi ante la implementaci\u00f3n de leyes y regula ciones tomadas de orga nismos reguladores internacionales. La mas reciente e importante accion ha sido la reconversi\u00f3n del Departamento de sistemas Indios de medicina y homeopatia, establecido en 1995, en el Departamento de Ayurveda, Yoga y Naturopatia, Un ani, Siddha y Homeopat\u00eda (AYUSH) en 2003. Este departamento a hecho progresos c ontinuos en la regulaci\u00f3n de sist emas tradicionales con \u00e9nfasis en aumentar los niveles de educ aci\u00f3n, control de calidad y estandarizaci\u00f3n de drogas, aumentando la disponibilidad de materiales crudos, investigando y desarrollando as\u00ed como concienciando de la eficacia de los sistemas tradic ionales tanto a nivel domes tico como internacional. Palabras clave: India, medicamentos herbarios, re Ayurveda, providing medicinal compounds and as starting points for the development of synthetic analogues. In some particular cases, such as antitumor drugs, about 60% of the medicines currently available on the market and most of those in the late stages of clinical trials are derived from natural products, mainly from higher (Calixto, 2000). With the of screening programs and Regulation of Traditional Medicines in India Mukherjee et al. Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 130 the increasing interest in the reservoir of untested natural products, re drug developments will be based, at least in part, on products. India is having a well-recorded and well practiced knowledge of traditional herbal medicine (Kamboj, 2000). Medicinal herbs have been in use in one form or another, under indigenous systems of medicine like Ayurveda, Siddha and Unani. India is a major exporter of raw medicinal and aromatic plants and processed plant-based drugs. It is generally estimated that over 6000 plants in India are in use in traditional, folk and herbal medicine , representing about 75% of the medicinal needs of the third world countries (Dubey et al., 2004; 2002a). background, needs to increase its share in the world market. The US market is expected to grow to 5 trillion US dollars in 2050 (Joshi et al., 2004; Rai et al., 2006). This can be achieved by judicious product identification based on diseases found in the developed world for which no medicine or only palliative therapy is available; such improvement in the processes of regulation is the need of the day, since it will be possible for the people to obtain high quality herbal medicines (Calixto, 2000; Verproote, 2005). In this context, India has acknowledged the need for addressing the issue of the use of herbal medicines along with other regulatory measures. Not many nations have launched initiatives to inculcate traditional herbal regulatory measures into their drug regulatory system. In the herbal boom world wide it is estimated that high quality phyto-medicinals ein should have wide knowledge in every respects of the production and utilization of herbals. In this context quality control guidelines have been reported. (Mukherjee, 2002b). In India, separate Department or the Indian System of Medicine and Homeopathy (ISM & H) has been made who are specially dealing with the rules and regulations for the herbals along with the Drugs and Cosmetic act and rules which has come up with the rules for the implementation of GMP in herbals, which will not only help to make the quality herbal products but also to safeguard the adverse effects of the herbals too. An attempt has been made to make a complete review on every aspect of the development in the regulations of Indian System of Medicine. THE ANCIENT INDIAN TRADITIONAL MEDICINE The World Health Organization (WHO) estimates that about 80% of the populations living in the developing countries rely almost medicine care needs. India has an ancient heritage of traditional medicine. India possesses a well-recorded and traditionally well-practiced knowledge of herbal medicine. It is generally estimated that over 6000 plants in India are in u se in traditional, folk and herbal medicine, representing about 75% of the medicinal needs of the world countries. Materia medica of India provides lots of information on the folklore practices and traditional aspects of therapeutically important natural products. Indian Materia medica includes about 2000 drugs of natural origin almost all of which are derived from different traditional system and folklore practices. Out of these drugs derived from traditional system, 400 are of mineral and animal origin while the rest are of vegetable origin. Three of the ten most widely selling mainly consists of three major systems namely Ayurveda, Siddha and Unani (ASU). With the emerging interest in the world to follow Indian system of Medicine, the government of India is trying their best to bring out therapeutic approaches available in original system of medicine as well as help in generating data to put these products on national health care program (Mukherjee, 2002b, 2003a,2006). Ayurveda Ayurveda is a system of healing from India. The origin of Ayurveda has been lost in prehistoric antiquity, but their characteristic concepts appeared to have been nurtured between 2500 and 500BC in India (Mukherjee, 2001). Ayurveda is usually translated as \"the science of life\" (Anonymous, 2006a). In Indian system of traditional medicine, it is accepted as the oldest written medical system that is also supposed to Formulations Regulation Medicines in India Mukherjee et al. Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 131 years it has developed into twenty-two specialties. Despite in the hands of an experienced practitioner, and most of the herbs used are fairly saf Unfortunately, lack of regulation, issues in some products has led to serious concerns about the safety of ayurvedic medicines. Siddha System of Medicine Siddha system is one of the oldest systems of medicine in India, which blends medicine and mysticism. The word Siddha was coined from word 'Siddhi', which attainment and the art was practiced by men Siddha medicine resembles the Ayurveda, they possess different origin. Siddha medicine originated from the south of Indian subcontinent of pulse, urine, eyes, study of voice, color of body, tongue and the status of the digestive system. The Siddha system of medicine emphasizes that medical treatment is oriented not merely to disease but has to take into account the patient, environment, the meteorological consideration, age, physical condition, physiological constitution etc. This means the treatment has to be individualistic which ensures lesser chance of committing mistakes in medicine) is a system of medicine practiced today in the South Asian countries of India, Pakistan, and Bangladesh. Its origins lie in ancient Greek, Arabic, and Persian medicine. In India, Arabs introduced the Unani system of medicine, which was developed by the Mughal emperors who invaded India. (Williamson, 2006; Mukherjee and Wahile, 2006). Here diseases are considered as a natural process and its symptoms are the reaction of the body to the diseases. Unani, with philosophy, Specifications range of behaviors and events that could lead to sickness and disease are outlined in the Unani texts. In common with many traditional sources of medicine, emphasizes the use imbalances which contribute to disease. The choices of foods and the manner in which they are prepared are considered to be among the most root causes of imbalances. With the emerging interest in the world to adopt and study the traditional system and to exploit their potentials based on different healthcare systems, Government of India is exploring several possibilities for the evaluation of these systems to bring out therapeutic approaches available in original system of medicine as well as to help in generating data to put these products on national health care program. The Indian herbal products including Ayurveda, Unani, Siddha and Homeopathy are regulated & Cosmetics Act and of control has been 1940, Govt. of India; various aspects of the regulation on control of herbal medicinal products has been described in Table 1. DEPARTMENT OF AYURVEDA, YOGA & NATUROPATHY, UNANI, SIDDHA AND HOMOEOPATHY (AYUSH) The Department of Indian Systems of Medicines and Homoeopathy (ISM & H) established in Ministry of Health & Family Welfare in March, 1995 was renamed as the Department of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy (AYUSH) in November, 2003. year Emphasis schemes which address the thrust areas identified by the Department like up gradation of educational standards, quality control and standardization of drugs, improving the availability of raw material, research and development and awareness generation about the efficacy of the systems domestically et al. Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 132 Table 1: Regulatory aspects of natural products ba of misbranded: 9 If colored or coated to the damage or made appear better than therapeutic value 9 If it is not manner 9 If label or consists or If prepared, packed insanitary or substance 9 colour other one which is prescribed 9 harmful or toxic substance 9 If any substance to its strength. ASU drugs 9 If it is sold or offered under another name. 9 If it is an imitation or substitute for another drug 9 If the label or container bears the name of an individual or company which is fictious. 9 If it has been substituted by other drug Regulation of manufacture No person shall manufacture for sale ASU drug except in accordance with prescribed standards. Prohibition of patent proprietary medicine, 9 contravention to any of the provisions of the act Power of Central Government to prohibit manufacture of ASU Drug involve any risk to human beings or animals 9 not have person with the prescribed qualification and do not have any financial interest in ASU drug. Inspectors. 33G. Central or State person with the pres cribed qualification and do not have any financial interest in ASU drug. Penalty for manufacture, sale, etc., of of this Chapter. 33I manufactures for sale or for distribution of any ASU drugs deemed to be adulterated or without less than two years but which may ex tend to six years and with fine not less than 5000 INR. Confiscation. be instituted except by an Inspector. \u0083 No Court inferior to that of a [Metropolitan Magistrate] or of a [Judicial Magistrate] of the first class shall try an offence punishable under this Chapter. Power of Central Government rules. 33N The Central Government may -after consultati on with, or on the recommendation of, the Board- and after previous publication by notification in the make the purpose of giving effect to the Siddha) or drugs. 153 application the grant or renewal of a licence to manufacture for sale any ASU drugs shall be made in Form 24-D to the Licensing Authority along with a 157 being fulfilled, a licence to manufacture 25-D. renewal of a loan licence to manufacture for sale of any ASU drugs shall be made in Form 25-E to the Licensing Authority along with a fee of rupees thirty. Certificate of award of G.M.P. of Ayurveda, Siddha Unani 155 B the requirements GMP of ASU drugs as laid down in Schedule T. Standards to be complied with in manufacture for sale or for distribution of Ayurvedic, Siddha and Unani Drugs. 168. Single Asavas and Arishtas : The upper limit of alcohol as self generated should not v/v. Regulation in Mukherjee et al. Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 133 Department of AYUSH 1945 in the Gazette of India. The draft claims that the certificate of Good Manufacturing Practices Ayurveda, laid down in Schedule T (Mukherjee et al., The Good Manufacturing Practices (GMP) is prescribed to ensure: i. Raw materials manufacture of drugs are authentic, of prescribed quality and are free from contamination. ii. The manufacturing process is as has been prescribed to maintain the standards. iii. Adequate quality control measures are adopted. iv. The manufactured drug is released be documented as a manual and kept for reference and inspection. FACTORY PREMISES The manufacturing plant should have adequate space for receiving and storing raw material, manufacturing process Quality Control store. also for water Supply, disposal of waste, container's cleaning, stores, raw materials, packaging materials, finished goods stores, working space, health clothing, sanitation and hygiene or workers, medical services, machinery and equipments, batch manufacturing records, distribution records, record of market complaints, quality control and the requirements for sterile products viz., manufacturing areas, precautions against contamination and mix. It also provided the list of recommended machinery, equipment in-house quality control section. HEAVY METAL CONTENTS Heavy metal contamination may be a particular problem with traditional remedies from India, which are currently becoming prevalent in the USA, Australia, Europe and other countries. Due to unsatisfactory Agricultural and cultivation practices relating in Siddha & Unani (ASU) general environmental speaking, heavy metals are not contaminants of such drugs but are seen as active ingredients by proponents of traditional Indian medicine (Ernst, 2002). The Indian government introduced regulations in October 2005 with regard to heavy metal content in Ayurvedic formulations. De partment of Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy (AYUSH), in an order made Lead, Mercury and of every \"Quality Control Methods for Medicinal Plants & Materials\". In case of Mercury, the permissible limit will be one ppm. Conspicuous display on the container of purely herbal ASU drugs to be exported the s \"Heavy metals the State Drug against the defaulting manufacturers for revocation of their licenses under Rules 157, 158 and 159 of the Drugs & Cosmetics Rules, 1945 for failure to comply with the Good Manufacturing Practices notified under compliance ASU drug manufacturers of the provisions of Rule 161 (1) and (2) relating to displaying on the label of the container or package of an Ayurveda, Siddha and Unani drug, the true list of all the ingredients (official and botanical names) used in the manufacture of the preparation together with the quantity of each of the ingredients incorporated therein. In case all the ingredients cannot be mentioned on the label because of their large number the same shall be indicated in the leaflet to be inserted in the package. Further that the container of a medicine shall conspicuously display the words 'Caution to be taken under medical supervision' if the list of ingredients contains a Regulation of Traditional Medicines in India Mukherjee et al. Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 134 substance specified in Schedule E(1) of the PLANTS BOARD Government of India decided to establish an independent called \"Na tional Medicinal Plants Board\" under the chairpersonship of ministry of health and family welfare. Its objectives to import or export, value addition, research and development, agro technology development and IPR related issues etc. The main objective of establishing the Board is to have an ag ency at National level which would be responsible to co-ordinate all matters relating to development of medicinal cost-effective cultivation and etc. raw material in order to protect, sustain and develop this sector (Anonymous, 2002a). To achieve these objectives 27 state medicinal plants boards were established. The National Medicinal Plants Board has been setup as a follow-up of recommendations of the Task Force on conservation and sustainable utilization medicinal standards for Ayurveda, Siddha and Unani medicine both for single and compound drugs is an essential item of work. The Indian ministry had taken up the task of developing pharmacopoeial of Ayurveda, Siddha, Unani and Homoeopathy and to prescribe working standards for single drugs as well as compound formulations. TRADITIONAL KNOWLEDGE DIGITAL LIBRARY (TKDL) Since time immemorial, India has a rich traditional knowledge. Documentation of this existing knowledge, available in public domain, on various traditional systems of medicine has become imperative to safeguard the sovereignty of this traditional knowledge and to protect them from being misused in patenting on non-patentable inventions. The TKDL is an proprietary database, which is fully protected under nati onal and international laws of Intellectual Property Rights. TKDL, based on a novel way of decodification software, allows automatic conversion of information from Sanskrit languages. information includes names of plants, under their modern be taken up from 45 Ayurvedic books, out of which 23,000 will be excluding the duplicate references. on identification So far more than 34000 formulations have been identified from the Ayurveda texts and they have been checked for the duplicates. Transcription of 25000 formulations has been completed from 14 texts out of the targeted 45 texts. A similar work is also being carried out in other Indian system of Medicines. The Indian government has also established 10 new drug testing laboratories for Indian systems of medicine and is upgrading existing laboratories to provide high quality evidence to licensing authorities of the safety and quality of herbal medicines. This replaces an ad hoc system of testing that was considered unreliable. These laboratories are also involved in ISM drug industry and drug inspecting staff on standardization and of medicine also have been initiated. These will document the safety and efficacy of the prescriptions and provide the basis in India Mukherjee et al. Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 135 THE INDIAN MEDICINES DEVELOPMENT CORPORATION BILL, 2005 In the ancient times, India has been the leader in the medicines. Several systems, mostly indigenous, for manufacture of medicines. Later allopathy system of medicine came into being. Allopathy system being mostly of chemicals has its own effects while temporarily own side effects which spoil the body system. Further the system is costlier also and poor people cannot afford to use this system. India has immense resources of herbal plants. They have not been properly explored and exploited. Moreover, there is a of system of medicines. Therefore, is proposed to establish a Corporation exclusively promote and develop system herbal plants iii. To manufacture and process Indian system of medicine; iv. To distribute and set up outlets for selling Indian system of medicine; v. To extend financial and technical assistance to persons involved in research in Indian system of medicine; vi. To export medicines based on Indian system; and vii. To advocate the extensive use of Indian system of medicine. TRADITIONAL HERBAL MEDICINES ACT, 2006 The market in the urban and semi-urban area in India is full of traditional herbal preparations. These medicines claim to cure general fatigue to diabetes to cancer. According to a report, a causal and random checking and testing of these medicines by the Department of Pharmacology of one of the premium referral hospitals in India revealed that many of them were contaminated containing steroids which in the long run could lead to suppression of immune system, growth retardation in children, diabetes and cataracts. Under the pretext of ancient texts and without any legal requirement of license sell these medicines, these traditional herbal medicines act, 2006 was introduced in the Indian Parliament in May, 2006 to regulate the sale of the traditional herbal medicines which are being marketed without any license and control under the cover of being manufactured by formulation provided in the and verification of matters connected therewith and (Anonymous, are: To ensure quality control of the medicines. (ii) To arrange to verify the ingredient of any medicine. (iii) To act on the complaint received in respect of any medicine. (iv) To recommend cancellation of license for selling of any traditional herbal medicine. (v) To make the people aware about its findings of various spurious medicines. (vi) To conduct sample checking of every manufacturer at least once in a year through its laboratories. (vii) Any other function that may be assigned. According to the act no traditional herbal medicine shall be sold or made available over the counter, every retailer or seller of traditional herbal medicines shall to obtain a license to traditional herbal medicines from the Authority in such manner as may be prescribed. Every manufacturer of traditional herbal medicine shall list the ingredients of each medicine on the packing of the medicine along with their accurate quantity. Every of traditional herbal medicine shall clearly and boldly indicate on the packaging of the medicine any side effects and warning of contraindications in such manner as may be prescribed. CONCLUSION The market for medicinal plants is difficult to obtain as there is no clear distinction between food, and aromatic usage of these plants. Facing multi-billion dollar international trade of herbal medicines, many countries in Asia are positioning themselves this Regulation Medicines in India Mukherjee et al. Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 136 business and implement appropriate regulatory measures to safeguard public health. To maximize the utilizations of the natural resources, there should be an international co-ordination leading to harmonization on explored further in the context of modern development. Most of the herbal medicines in the world originate from developing countries, although the export volumes from most of these countries are small. There are ample opportunities for these countries to expand their global export. The Indian government has drawn up regulations for good manufacturing practice for traditional Indian systems of medicine such as ayurveda, siddha, and unani, so that the industry can compete in international markets. Government of India has taken various initiatives to improve the herbal drug standards and promote Indian system of medicine. Government of India has been stiffening the herbal drug regulations from time to time by establishing various bodies to control the manufacture and natural products. REFERENCES Anonymous, 2002a. AYUSH, Govt. of India. 2002. Final Report. mohfw.nic.in /Annual0506/Ayush%20annual%20report%20final.pdf Anonymous, 2003a. Ministry Of Health And Family Welfare (Department Of Indian Systems Of Medicine And Homoeopathy), Notification. http://www.ipapharma.org/Schedule%20T.pdf . Anonymous, 2005a. The Bill, 2005. http://164.100.24.208/ls/Bills/144,2005.pdf . Anonymous, 2006a. Department of Ayurveda, Siddha and Homoeopathy) (AYUSH ) Government Health & Family Welfare Dated: October 14, 2005 o r d e r Anonymous, 2006b. Ayurveda Fact sheet. http://www.catie.ca/pdf/supple-e/ayurveda.pdf P a g e 1-3. Anonymous, 2006c. The Traditional Herbal Medicines (Regulation of Sale and Compulsory Evidence Based Trial) Bill, 2006. http://rajyasabha.nic.in/bills-ls- rs/2006/XXXVIII_2006.pdf Anonymous, 2007. Hope for Ayurveda as US FDA German Herbal drug. http://www.techno- opportunity. Sci P, Warude D and Patwardhan B. 2004. Molecular technology. to Evaluation of Botanicals. Business pp.1-6. PK. 2002b. Problem s and prospects for the in herbal drugs in Indian systems of medicine. 635-644. Mukherjee K. Advances In: Chemistry for Green Environment. Srivastava MM, Sanghi House, Maiti K, K, Approaches towards Drug Development from Ayurveda and other System Ethanopharmacol al. Bol. Latinoam. Caribe Plant. Med. Aromaticas Vol. 6 (4) 2007 137 Rai S, Mukherjee K, Mal M, Atul W, Saha BP, Pulok K. of medicinal plants in a globalized world. Promotion and Development of Botanicals with International Coordination. Allied Book Agency, Kolkata, India. for pharmacists, Pharm. J. 276: 108-110. Laboratorio Regional Latinoamericano sobre Medicina Tradicional Bol. Latinoam. Caribe Plant. Med. Aromat. Vol. 6 (4) 2007 138 Entre el 10 y 12 de Mayo pasado se realiz\u00f3 en la ciudad de Leticia, Colombia el Laboratorio Regional Latinoamericano sobre Medicina Tradicional \"Di\u00e1logo de saberes: plantas medicinales, salud y cosmovisiones. Experiencias de medicina tradicional al servicio de la salud p\u00fablica\", Este evento fue organizado por AIFO, M onserrate, Cooperazione Italiana, COE, MLAL Progettomondo, Universidad de Los Andes y Universidad Nacional de Colombia - Sede Leticia. Cont\u00f3 con la organizaci\u00f3n y sacrificio que bien valieron la pena de Enrico Neri, quien encabez\u00f3 el evento. Cont\u00f3 con la participaci\u00f3n de destacados investigadores internacionales: Armando Herrera (M\u00e9xico) y Miguel Angel Guti\u00e9rrez (M\u00e9xico), Elaine Elisabetsky (Brasil), Elena Li (Per\u00fa), Jorge Alonso (Argentina) y Jos\u00e9 Luis Mart\u00ednez (Chile). Adem\u00e1s de varios investigadores de Colombia y tambi\u00e9n muchos grupos \u00e9tnicos. El logo del evento y algunas fotos se muestran a continuaci\u00f3n: Ldo. Jos\u00e9 L. Martinez Editor Jefe de BLACPMA Foto 1: Parte de los participante s posan para la foto oficial. Foto 2: El Editor Jefe de BLACPMA junto a Enrico Neri. Foto 3: Invitados junto a Enrico Neri, de izquierda a derecha: Enrico Neri, Miguel Angel Guti\u00e9rrez, Elena Li, Jos\u00e9 Luis Mart\u00ednez, Jorge Alonso, Elaine Elisabetsky y Harold Gomez. Foto 4 Jos\u00e9 Luis Mart\u00ednez junto a Humberto Andoque, cacique y jefe m\u00e1ximo de la Comunidad Andoque. Canto IX Desde all\u00ed da\u00f1osos vientos llev\u00e1ronme nueve d\u00edas por el ponto, abundante en peces, y al d\u00e9cimo arribamos a la tierra de los lot\u00f3fagos, que se alimentan con un florido manjar. Saltamos en tierra, hicimos aguada, y pronto los compa\u00f1eros empezaron a comer junto a las veleras naves. Y despu\u00e9s que hubimos gustado los alimentos y la bebida, envi\u00e9 algunos compa\u00f1eros -dos varones a quienes escog\u00ed e hice acompa\u00f1ar por un tercero que fue un heraldo- para que averiguaran cu\u00e1les hombres com\u00edan el pan en aquella tierra. Fu\u00e9ronsepronto y junt\u00e1ronse con los lot\u00f3fagos, que no tramaron ciertamente la perdici\u00f3n de nuestros amigos; pero les dieron a comer loto, y cuantos probaron este fruto, dulce como la miel, ya no quer\u00edan llevar noticias ni volverse; antes deseaban permanecer con los lot\u00f3fagos, comiendo loto, sin acordarse de volver a la patria. Mas yo los llev\u00e9 por fuerza a las c\u00f3ncavas naves y, aunque lloraban, los arrastr\u00e9 e hice atar debajo de los bancos. Y mand\u00e9 que los restantes fieles compa\u00f1eros entrasen luego en las veloces embarcaciones: no fuera que alguno comiese loto y no pensara en la vuelta. Hici\u00e9ronlo en seguida y, sent\u00e1ndose por orden en los bancos, comenzaron a batir con los remos el espumoso mar. Homero, La Odisea. Canto IX (TRADUCCION DE LUIS SEGALA Y ESTALELLA) Disponible en http://www.odisea.com.mx/ Plantas Medicinales en la LiteraturaISSN 0717 "}